<?xml version="1.0" encoding="utf-8"?>
<!DOCTYPE html PUBLIC "-//W3C//DTD XHTML 1.0 Transitional//EN" "http://www.w3.org/TR/xhtml1/DTD/xhtml1-transitional.dtd">
<html xmlns="http://www.w3.org/1999/xhtml" xml:lang="en" lang="en">
    
    <head><meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
        <!-- AppResources meta begin -->
        <meta name="paf-app-resources" content="" />
                 <script type="text/javascript">var ncbi_startTime = new Date();</script>
            
        <!-- AppResources meta end -->
        
        <!-- TemplateResources meta begin -->
        <meta name="paf_template" content="" />

        <!-- TemplateResources meta end -->
        
        <!-- Logger begin -->
        <meta name="ncbi_db" content="books" /><meta name="ncbi_pdid" content="book-part" /><meta name="ncbi_acc" content="NBK1201" /><meta name="ncbi_domain" content="gene" /><meta name="ncbi_report" content="record" /><meta name="ncbi_type" content="fulltext" /><meta name="ncbi_objectid" content="" /><meta name="ncbi_pcid" content="/NBK1201/" /><meta name="ncbi_pagename" content="Neurofibromatosis 2 - GeneReviews® - NCBI Bookshelf" /><meta name="ncbi_bookparttype" content="chapter" /><meta name="ncbi_app" content="bookshelf" />
        <!-- Logger end -->
        
        <title>Neurofibromatosis 2 - GeneReviews® - NCBI Bookshelf</title>
        
        <!-- AppResources external_resources begin -->
        <link rel="stylesheet" href="/core/jig/1.14.8/css/jig.min.css" /><script type="text/javascript" src="/core/jig/1.14.8/js/jig.min.js"></script>

        <!-- AppResources external_resources end -->
        
        <!-- Page meta begin -->
        <meta name="robots" content="INDEX,FOLLOW,NOARCHIVE" /><meta name="citation_inbook_title" content="GeneReviews® [Internet]" /><meta name="citation_title" content="Neurofibromatosis 2" /><meta name="citation_publisher" content="University of Washington, Seattle" /><meta name="citation_date" content="2018/03/15" /><meta name="citation_author" content="D Gareth Evans" /><meta name="citation_pmid" content="20301380" /><meta name="citation_fulltext_html_url" content="https://www.ncbi.nlm.nih.gov/books/NBK1201/" /><meta name="citation_keywords" content="Neurofibromatosis Type II" /><meta name="citation_keywords" content="NF2" /><meta name="citation_keywords" content="NF2" /><meta name="citation_keywords" content="Neurofibromatosis Type II" /><meta name="citation_keywords" content="Merlin" /><meta name="citation_keywords" content="NF2" /><meta name="citation_keywords" content="Neurofibromatosis 2" /><link rel="schema.DC" href="http://purl.org/DC/elements/1.0/" /><meta name="DC.Title" content="Neurofibromatosis 2" /><meta name="DC.Type" content="Text" /><meta name="DC.Publisher" content="University of Washington, Seattle" /><meta name="DC.Contributor" content="D Gareth Evans" /><meta name="DC.Date" content="2018/03/15" /><meta name="DC.Identifier" content="https://www.ncbi.nlm.nih.gov/books/NBK1201/" /><meta name="description" content="Neurofibromatosis 2 (NF2) is characterized by bilateral vestibular schwannomas with associated symptoms of tinnitus, hearing loss, and balance dysfunction. The average age of onset is 18 to 24 years. Almost all affected individuals develop bilateral vestibular schwannomas by age 30 years. Affected individuals may also develop schwannomas of other cranial and peripheral nerves, meningiomas, ependymomas, and, very rarely, astrocytomas. Because NF2 is considered an adult-onset disease, it may be underrecognized in children, in whom skin tumors and ocular findings (retinal hamartoma, thickened optic nerves, cortical wedge cataracts, third cranial nerve palsy) may be the first manifestations. Mononeuropathy that occurs in childhood is an increasingly recognized finding; it frequently presents as a persistent facial palsy or hand/foot drop." /><meta name="og:title" content="Neurofibromatosis 2" /><meta name="og:type" content="book" /><meta name="og:description" content="Neurofibromatosis 2 (NF2) is characterized by bilateral vestibular schwannomas with associated symptoms of tinnitus, hearing loss, and balance dysfunction. The average age of onset is 18 to 24 years. Almost all affected individuals develop bilateral vestibular schwannomas by age 30 years. Affected individuals may also develop schwannomas of other cranial and peripheral nerves, meningiomas, ependymomas, and, very rarely, astrocytomas. Because NF2 is considered an adult-onset disease, it may be underrecognized in children, in whom skin tumors and ocular findings (retinal hamartoma, thickened optic nerves, cortical wedge cataracts, third cranial nerve palsy) may be the first manifestations. Mononeuropathy that occurs in childhood is an increasingly recognized finding; it frequently presents as a persistent facial palsy or hand/foot drop." /><meta name="og:url" content="https://www.ncbi.nlm.nih.gov/books/NBK1201/" /><meta name="og:site_name" content="NCBI Bookshelf" /><meta name="og:image" content="https://www.ncbi.nlm.nih.gov/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" /><meta name="twitter:card" content="summary" /><meta name="twitter:site" content="@ncbibooks" /><meta name="bk-non-canon-loc" content="/books/n/gene/nf2/" /><link rel="canonical" href="https://www.ncbi.nlm.nih.gov/books/NBK1201/" /><link rel="stylesheet" href="/corehtml/pmc/css/figpopup.css" type="text/css" media="screen" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books.min.css" type="text/css" /><link rel="stylesheet" href="/corehtml/pmc/css/bookshelf/2.22/css/books_print.min.css" type="text/css" media="print" /><style type="text/css">p a.figpopup{display:inline !important} .bk_tt {font-family: monospace}  .first-line-outdent .bk_ref {display: inline}  .body-content h2, .body-content .h2  {border-bottom: 1px solid #97B0C8} .body-content h2.inline {border-bottom: none} a.page-toc-label , .jig-ncbismoothscroll a {text-decoration:none;border:0 !important} .temp-labeled-list  .graphic {display:inline-block !important} .temp-labeled-list  img{width:100%}</style><script type="text/javascript" src="/corehtml/pmc/js/jquery.hoverIntent.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/common.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/large-obj-scrollbars.min.js"> </script><script type="text/javascript">window.name="mainwindow";</script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/book-toc.min.js"> </script><script type="text/javascript" src="/corehtml/pmc/js/bookshelf/2.22/books.min.js"> </script><meta name="book-collection" content="NONE" />

        <!-- Page meta end -->
    <link rel="shortcut icon" href="//www.ncbi.nlm.nih.gov/favicon.ico" /><meta name="ncbi_phid" content="CE887A1AE03F26D1000000000A9503B0.m_12" />
<meta name='referrer' content='origin-when-cross-origin'/><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3852956/3985586/3808861/4121862/3974050/3917732/251717/4098876/14534/45193/4113719/3849091/3984811/3751656/4033350/3840896/3577051/3852958/4008682/3881636/3579733/4062871/12930/3964959/3854974/36029/4128070/9685/3549676/3609192/3609193/3609213/3395586.css" /><link type="text/css" rel="stylesheet" href="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/css/3411343/3882866.css" media="print" /></head>
    <body class="book-part">
        <div class="grid">
            <div class="col twelve_col nomargin shadow">
                <!-- System messages like service outage or JS required; this is handled by the TemplateResources portlet -->
                <div class="sysmessages">
                    <noscript>
	<p class="nojs">
	<strong>Warning:</strong>
	The NCBI web site requires JavaScript to function. 
	<a href="/guide/browsers/#enablejs" title="Learn how to enable JavaScript" target="_blank">more...</a>
	</p>
	</noscript>
                </div>
                <!--/.sysmessage-->
                <div class="wrap">
                    <div class="page">
                        <div class="top">
                            <div class="universal_header" id="universal_header"><ul class="inline_list jig-ncbimenu ui-ncbimenu resources_list" id="navcontent"><li class="ui-ncbimenu-item-leaf ui-ncbimenu-item-first ui-helper-reset ui-ncbimenu-item-no-hlt"><a class="ui-ncbimenu-link-first" href="/" role="banner" title="NCBI Home" id="ncbihome" accesskey="1"><span class="offscreen_noflow">NCBI</span><img src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/img/28977" class="ncbi_logo" title="NCBI" alt="NCBI Logo" /></a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#maincontent" title="Skip to the content" tabindex="0" accesskey="3">Skip to main
                        content</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="#navcontent" title="Skip to the navigation" tabindex="0" accesskey="4">Skip to
                        navigation</a></li><li id="resource-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first ui-helper-reset"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#resources">Resources</a></li><li id="all-howtos-menu" class="topmenu ui-helper-reset ui-ncbimenu-item-first"><a class="ui-ncbimenu-first-link-has-submenu ui-ncbimenu-link-first topanchor expandDown" href="/static/header_footer_ajax/submenu/#howto">How To</a></li><li class="offscreen_noflow ui-ncbimenu-item-skip access"><a href="/guide/browsers/#accesskeys" title="About My NCBI Accesskeys" tabindex="0" accesskey="0">About NCBI Accesskeys</a></li></ul><div class="myncbi"><span id="myncbiusername" style="display:none"><a href="/account/settings/" id="mnu" title="Edit account settings"></a></span><a accesskey="2" href="/myncbi/" id="myncbi" style="display:none">My NCBI</a><a href="/account/" id="sign_in">Sign in to NCBI</a><a href="/account/signout/" id="sign_out" style="display:none">Sign Out</a></div></div>
                            <div class="header">
    <div class="res_logo"><h1 class="res_name"><a href="/books/" title="Bookshelf home">Bookshelf</a></h1><h2 class="res_tagline"></h2></div>
    <div class="search"><form method="get" action="/books/"><div class="search_form"><label for="database" class="offscreen_noflow">Search database</label><select id="database"><optgroup label="Recent"><option value="books" selected="selected" class="last" data-ac_dict="bookshelf-search">Books</option></optgroup><optgroup label="All"><option value="gquery">All Databases</option><option value="assembly">Assembly</option><option value="biocollections">Biocollections</option><option value="bioproject">BioProject</option><option value="biosample">BioSample</option><option value="biosystems">BioSystems</option><option value="books" data-ac_dict="bookshelf-search">Books</option><option value="clinvar">ClinVar</option><option value="cdd">Conserved Domains</option><option value="gap">dbGaP</option><option value="dbvar">dbVar</option><option value="gene">Gene</option><option value="genome">Genome</option><option value="gds">GEO DataSets</option><option value="geoprofiles">GEO Profiles</option><option value="gtr">GTR</option><option value="homologene">HomoloGene</option><option value="ipg">Identical Protein Groups</option><option value="medgen">MedGen</option><option value="mesh">MeSH</option><option value="ncbisearch">NCBI Web Site</option><option value="nlmcatalog">NLM Catalog</option><option value="nuccore">Nucleotide</option><option value="omim">OMIM</option><option value="pmc">PMC</option><option value="popset">PopSet</option><option value="probe">Probe</option><option value="protein">Protein</option><option value="proteinclusters">Protein Clusters</option><option value="pcassay">PubChem BioAssay</option><option value="pccompound">PubChem Compound</option><option value="pcsubstance">PubChem Substance</option><option value="pubmed">PubMed</option><option value="snp">SNP</option><option value="sparcle">Sparcle</option><option value="sra">SRA</option><option value="structure">Structure</option><option value="taxonomy">Taxonomy</option><option value="toolkit">ToolKit</option><option value="toolkitall">ToolKitAll</option><option value="toolkitbookgh">ToolKitBookgh</option></optgroup></select><div class="nowrap"><label for="term" class="offscreen_noflow" accesskey="/">Search term</label><div class="nowrap"><input type="text" name="term" id="term" title="Search Books. Use up and down arrows to choose an item from the autocomplete." value="" class="jig-ncbiclearbutton jig-ncbiautocomplete" data-jigconfig="dictionary:'bookshelf-search',disableUrl:'NcbiSearchBarAutoComplCtrl'" autocomplete="off" data-sbconfig="ds:'no',pjs:'no',afs:'no'" /></div><button id="search" type="submit" class="button_search nowrap" cmd="go">Search</button></div></div></form><ul class="searchlinks inline_list"><li>
                        <a href="/books/browse/">Browse Titles</a>
                    </li><li>
                        <a href="/books/advanced/">Advanced</a>
                    </li><li class="help">
                        <a href="/books/NBK3833/">Help</a>
                    </li></ul></div>
</div>

                            
                            
                        <!--<component id="Page" label="headcontent"/>-->
                            
                        </div>
                        <div class="content">
                            <!-- site messages -->
                            <!-- Custom content 1 -->
<div class="col1">
    
</div>

<div class="container">
    <div id="maincontent" class="content eight_col col">
        <!-- Custom content in the left column above book nav -->
        <div class="col2">
            
        </div>
        
        <!-- Book content -->
        

        <!-- Custom content between navigation and content -->
        <div class="col3">
            
        </div>
        
        <div class="document">
            <div class="pre-content"><div><div class="bk_prnt"><p class="small">NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.</p><p>Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. </p></div><div class="iconblock clearfix whole_rhythm no_top_margin bk_noprnt"><a class="img_link icnblk_img" title="All GeneReviews" href="/books/n/gene/"><img class="source-thumb" src="/corehtml/pmc/pmcgifs/bookshelf/thumbs/th-gene-lrg.png" alt="Cover of GeneReviews®" height="100px" width="80px" /></a><div class="icnblk_cntnt eight_col"><h2>GeneReviews<sup>®</sup> [Internet].</h2><a data-jig="ncbitoggler" href="#__NBK1201_dtls__">Show details</a><div style="display:none" class="ui-widget" id="__NBK1201_dtls__"><div>Adam MP, Ardinger HH, Pagon RA, et al., editors.</div><div>Seattle (WA): <a href="http://www.washington.edu" ref="pagearea=page-banner&amp;targetsite=external&amp;targetcat=link&amp;targettype=publisher">University of Washington, Seattle</a>; 1993-2019.</div></div><div class="half_rhythm"><ul class="inline_list"><li style="margin-right:1em"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a></li></ul></div><div class="bk_noprnt"><form method="get" action="/books/n/gene/" id="bk_srch"><div class="bk_search"><label for="bk_term" class="offscreen_noflow">Search term</label><input type="text" title="Search GeneReviews" id="bk_term" name="term" value="" data-jig="ncbiclearbutton" /> <input type="submit" class="jig-ncbibutton" value="Search GeneReviews" submit="false" style="padding: 0.1em 0.4em;" /></div></form><div><ul class="inline_list"><li><a href="/books/n/gene/advanced/">GeneReviews Advanced Search</a></li><li style="margin-left:.5em"><a href="/books/n/gene/helpadvsearch/">Help</a></li></ul></div></div></div><div class="icnblk_cntnt two_col"><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/nf1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ncl/" title="Next page in this title">Next &gt;</a></div></div></div></div></div>
            <div class="main-content lit-style" itemscope="itemscope" itemtype="http://schema.org/CreativeWork"><div class="meta-content fm-sec"><h1 id="_NBK1201_"><span class="title" itemprop="name">Neurofibromatosis 2</span></h1><div itemprop="alternativeHeadline" class="subtitle whole_rhythm">Synonyms: Neurofibromatosis Type II, NF2</div><p class="contrib-group"><span itemprop="author">D Gareth Evans</span>, MD, FRCP.</p><a data-jig="ncbitoggler" href="#__NBK1201_ai__" style="border:0;text-decoration:none">Author Information</a><div style="display:none" class="ui-widget" id="__NBK1201_ai__"><div class="contrib half_rhythm"><span itemprop="author">D Gareth Evans</span>, MD, FRCP<div class="affiliation small">Director, Neurofibromatosis Clinic<br />Central Manchester Foundation NHS Trust Regional Genetic Service<br />St Mary's Hospital<br />Manchester, United Kingdom<div><span class="email-label">Email: </span><a href="mailto:dev@null" data-email="ku.shn.tfmc@snave.hterag" class="oemail">ku.shn.tfmc@snave.hterag</a></div></div></div></div><p class="small">Initial Posting: <span itemprop="datePublished">October 14, 1998</span>; Last Update: <span itemprop="dateModified">March 15, 2018</span>.</p><p><em>Estimated reading time: 29 minutes</em></p></div><div class="jig-ncbiinpagenav body-content whole_rhythm" data-jigconfig="allHeadingLevels: ['h2'],smoothScroll: false" itemprop="text"><div id="nf2.Summary" itemprop="description"><h2 id="_nf2_Summary_">Summary</h2><div><h4 class="inline">Clinical characteristics.</h4><p>Neurofibromatosis 2 (NF2) is characterized by bilateral vestibular schwannomas with associated symptoms of tinnitus, hearing loss, and balance dysfunction. The average age of onset is 18 to 24 years. Almost all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals develop bilateral vestibular schwannomas by age 30 years. Affected individuals may also develop schwannomas of other cranial and peripheral nerves, meningiomas, ependymomas, and, very rarely, astrocytomas. Because NF2 is considered an adult-onset disease, it may be underrecognized in children, in whom skin tumors and ocular findings (retinal hamartoma, thickened optic nerves, cortical wedge cataracts, third cranial nerve palsy) may be the first manifestations. Mononeuropathy that occurs in childhood is an increasingly recognized finding; it frequently presents as a persistent facial palsy or hand/foot drop.</p></div><div><h4 class="inline">Diagnosis/testing.</h4><p>The diagnosis of NF2 is established in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinical findings that meet the consensus diagnostic criteria and/or by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>NF2</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div><h4 class="inline">Management.</h4><p><i>Treatment of manifestations:</i> Treatment of vestibular schwannoma is primarily surgical; stereotactic radiosurgery, most commonly with the gamma knife, may be an alternative to surgery. Individuals with vestibular tumors need to be aware of insidious problems with balance and underwater disorientation, which can result in drowning. Treatment for hearing loss includes referral to an audiologist, lip-reading and sign language instruction, and possibly hearing aids and/or cochlear or brain stem implants.</p><p><i>Surveillance:</i> For <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at-risk individuals: annual MRI beginning at approximately age ten to 12 years and continuing until at least the fourth decade of life; hearing evaluation, including BAER testing; annual complete eye examination.</p><p><i>Agents/circumstances to avoid:</i> Radiation therapy of NF2-associated tumors, especially in childhood, when malignancy risks are likely to be substantially larger.</p><p><i>Evaluation of relatives at risk:</i> Early identification of relatives who have inherited the family-specific <i>NF2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> allows for appropriate surveillance, resulting in earlier detection and treatment of disease manifestations.</p></div><div><h4 class="inline">Genetic counseling.</h4><p>NF2 is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner. Approximately 50% of individuals with NF2 have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent, and 50% have NF2 as the result of a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. However, 25% to 30% of <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., single occurrence in a family) are mosaic for an <i>NF2</i> pathogenic variant. If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has other affected family members, each child of the proband has a 50% chance of inheriting the pathogenic variant. Once the <i>NF2</i> pathogenic variant has been identified in the family, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p></div></div><div id="nf2.Diagnosis"><h2 id="_nf2_Diagnosis_">Diagnosis</h2><div id="nf2.Suggestive_Findings"><h3>Suggestive Findings</h3><p>Neurofibromatosis type 2 (NF2) <b>should be suspected</b> in individuals with the following findings:</p><p><b>In children</b> (two or more of these findings)</p><ul><li class="half_rhythm"><div>A schwannoma at any location including intradermal</div></li><li class="half_rhythm"><div>Skin plaques present at birth or in early childhood (often plexiform schwannoma on histology)</div></li><li class="half_rhythm"><div>A meningioma, particularly non-meningothelial (non-arachnoidal) cell in origin</div></li><li class="half_rhythm"><div>A cortical wedge cataract</div></li><li class="half_rhythm"><div>A retinal hamartoma</div></li><li class="half_rhythm"><div>A mononeuropathy, particularly causing a facial nerve palsy, foot or wrist drop, or third nerve palsy</div></li></ul><p><b>In adults</b></p><ul><li class="half_rhythm"><div>Bilateral vestibular schwannomas</div></li><li class="half_rhythm"><div>Unilateral vestibular schwannoma accompanied by ANY TWO of the following: meningioma, schwannoma, glioma, neurofibroma, cataract in the form of subcapsular lenticular opacities or cortical wedge cataract</div></li><li class="half_rhythm"><div>Multiple meningiomas accompanied by EITHER of the following:</div><ul><li class="half_rhythm"><div>Unilateral vestibular schwannoma</div></li><li class="half_rhythm"><div>ANY TWO of the following: schwannoma, glioma, neurofibroma, cataract in the form of subcapsular lenticular opacities or cortical wedge cataract</div></li></ul></li></ul><p>For individuals of all ages with any of these clinical findings, having a <a class="def" href="/books/n/gene/glossary/def-item/first-degree-relative/">first-degree relative</a> with NF2 increases the likelihood of the disorder being present.</p></div><div id="nf2.Establishing_the_Diagnosis"><h3>Establishing the Diagnosis</h3><p>The diagnosis of NF2 <b>is established</b> in a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with clinical findings that meet the consensus diagnostic criteria and/or by identification of a <a class="def" href="/books/n/gene/glossary/def-item/heterozygous/">heterozygous</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>NF2</i> on <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> (see <a class="figpopup" href="/books/NBK1201/table/nf2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="fignf2Tmoleculargenetictestingusedin" rid-ob="figobnf2Tmoleculargenetictestingusedin">Table 1</a>).</p><div id="nf2.Clinical_Findings"><h4>Clinical Findings</h4><p>By the modified NIH consensus diagnostic criteria [<a class="bk_pop" href="#nf2.REF.baser.2002.715">Baser et al 2002</a>], NF2 is diagnosed in individuals with ONE of the following:</p><ul><li class="half_rhythm"><div>Bilateral vestibular schwannomas</div></li><li class="half_rhythm"><div>A <a class="def" href="/books/n/gene/glossary/def-item/first-degree-relative/">first-degree relative</a> with NF2 AND</div><ul><li class="half_rhythm"><div>Unilateral vestibular schwannoma OR</div></li><li class="half_rhythm"><div>ANY TWO of the following: meningioma, schwannoma, glioma, neurofibroma, cataract in the form of posterior subcapsular lenticular opacities or cortical wedge cataract</div></li></ul></li><li class="half_rhythm"><div>Unilateral vestibular schwannoma AND ANY TWO of the following: meningioma, schwannoma, glioma, neurofibroma, cataract in the form of posterior subcapsular lenticular opacities or cortical wedge cataract</div></li><li class="half_rhythm"><div>Multiple meningiomas AND</div><ul><li class="half_rhythm"><div>Unilateral vestibular schwannoma OR</div></li><li class="half_rhythm"><div>ANY TWO of the following: schwannoma, glioma, neurofibroma, cataract in the form of posterior subcapsular lenticular opacities or cortical wedge cataract</div></li></ul></li></ul><p>Note: Those with suspicious findings should have <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>.</p></div><div id="nf2.Molecular_Genetic_Testing"><h4>Molecular Genetic Testing</h4><p>Molecular genetic testing approaches can include a combination of <b><a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted testing</b> (single-gene testing, <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a>) and <b>comprehensive</b>
<b><a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (<a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> analysis, <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a>, <a class="def" href="/books/n/gene/glossary/def-item/exome-array/">exome array</a>, <a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a>) depending on the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Gene-targeted testing requires that the clinician determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>(s) are likely involved, whereas <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing does not. Because the <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> of NF2 is broad, individuals with the distinctive findings described in <a href="#nf2.Suggestive_Findings">Suggestive Findings</a> and adults who meet the consensus diagnostic criteria described in <a href="#nf2.Establishing_the_Diagnosis">Establishing the Diagnosis</a> are likely to be diagnosed using gene-targeted testing (see <b>Option 1</b>), whereas those in whom the diagnosis of NF2 has not been considered (especially in children) or those who do not fulfill the consensus diagnostic criteria are more likely to be diagnosed using genomic testing (see <b>Option 2</b>).</p><p><b>Option 1.</b> When the phenotypic and laboratory findings suggest the diagnosis of NF2, <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> approaches can include <b>single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing</b>, <b><a class="def" href="/books/n/gene/glossary/def-item/chromosomal-microarray/">chromosomal microarray</a> analysis (CMA)</b>, or use of a <b><a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b>:</p><ul><li class="half_rhythm"><div class="half_rhythm"><b>Single-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> testing.</b> Sequence analysis of <i>NF2</i> detects small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-gene deletions/duplications are not detected.</div><div class="half_rhythm">Perform <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> first. If no <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is found perform <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> to detect intragenic deletions or duplications.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>Chromosomal microarray analysis (CMA)</b> uses oligonucleotide or SNP arrays to detect genome-wide large deletions/duplications (including <i>NF2</i>) that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>.</div></li><li class="half_rhythm"><div class="half_rhythm"><b>A <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a></b> that includes <i>NF2</i> and other genes of interest (see <a href="#nf2.Differential_Diagnosis">Differential Diagnosis</a>) is most likely to identify the genetic cause of the condition at the most reasonable cost while limiting identification of variants of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a> and pathogenic variants in genes that do not explain the underlying <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>. Note: (1) The genes included in the panel and the diagnostic <a class="def" href="/books/n/gene/glossary/def-item/sensitivity/">sensitivity</a> of the testing used for each <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> vary by laboratory and are likely to change over time. (2) Some multigene panels may include genes not associated with the condition discussed in this <i>GeneReview</i>. (3) In some laboratories, panel options may include a custom laboratory-designed panel and/or custom phenotype-focused <a class="def" href="/books/n/gene/glossary/def-item/exome/">exome</a> analysis that includes genes specified by the clinician. (4) Methods used in a panel may include <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>, <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>, and/or other non-sequencing-based tests.</div><div class="half_rhythm">For this disorder a <a class="def" href="/books/n/gene/glossary/def-item/multigene-panel/">multigene panel</a> that also includes <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> is recommended (see <a class="figpopup" href="/books/NBK1201/table/nf2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object" rid-figpopup="fignf2Tmoleculargenetictestingusedin" rid-ob="figobnf2Tmoleculargenetictestingusedin">Table 1</a>).</div><div class="half_rhythm">For an introduction to multigene panels click <a href="/books/n/gene/app5/#app5.Multigene_Panels">here</a>. More detailed information for clinicians ordering genetic tests can be found <a href="/books/n/gene/app5/#app5.Multigene_Panels_FAQs">here</a>.</div></li></ul><p><b>Option 2.</b> When the diagnosis of NF2 is not considered because an individual has atypical phenotypic features (features in a child may not immediately suggest NF2) or does not meet the clinical consensus diagnostic criteria as an adult, <b>comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing</b> (which does not require the clinician to determine which <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>[s] are likely involved) is the best option. <b>Exome sequencing</b> is the most commonly used genomic testing method; <b><a class="def" href="/books/n/gene/glossary/def-item/genome-sequencing/">genome sequencing</a></b> is also possible. <b>Exome array</b> (when clinically available) may be considered if <a class="def" href="/books/n/gene/glossary/def-item/exome-sequencing/">exome sequencing</a> is non-diagnostic, to evaluate for a large <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> type of variant in <i>NF2</i>.</p><p>For an introduction to comprehensive <a class="def" href="/books/n/gene/glossary/def-item/genomic/">genomic</a> testing click <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing">here</a>. More detailed information for clinicians ordering genomic testing can be found <a href="/books/n/gene/app5/#app5.Comprehensive_Genomic_Testing_1">here</a>.</p><div id="nf2.T.molecular_genetic_testing_used_in" class="table"><h3><span class="label">Table 1. </span></h3><div class="caption"><p>Molecular Genetic Testing Used in Neurofibromatosis Type 2 (NF2)</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1201/table/nf2.T.molecular_genetic_testing_used_in/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__nf2.T.molecular_genetic_testing_used_in_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_nf2.T.molecular_genetic_testing_used_in_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Gene&#x000a0;<sup>1</sup></th><th id="hd_h_nf2.T.molecular_genetic_testing_used_in_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Test Method</th><th id="hd_h_nf2.T.molecular_genetic_testing_used_in_1_1_1_3" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Proportion of Probands with a Pathogenic Variant&#x000a0;<sup>2</sup> Detectable by This Method</th></tr></thead><tbody><tr><td headers="hd_h_nf2.T.molecular_genetic_testing_used_in_1_1_1_1" rowspan="2" scope="row" colspan="1" style="text-align:left;vertical-align:middle;"><i>NF2</i></td><td headers="hd_h_nf2.T.molecular_genetic_testing_used_in_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Sequence analysis&#x000a0;<sup>3</sup></td><td headers="hd_h_nf2.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">75%&#x000a0;<sup>4</sup></td></tr><tr><td headers="hd_h_nf2.T.molecular_genetic_testing_used_in_1_1_1_2" colspan="1" scope="row" rowspan="1" style="text-align:left;vertical-align:middle;">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a>&#x000a0;<sup>5,&#x000a0;6</sup> or CMA&#x000a0;<sup>7</sup></td><td headers="hd_h_nf2.T.molecular_genetic_testing_used_in_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">20%&#x000a0;<sup>8</sup></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt>1. </dt><dd><div id="nf2.TF.1.1"><p class="no_margin">See <a href="/books/NBK1201/#nf2.molgen.TA">Table A. Genes and Databases</a> for <a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> and protein.</p></div></dd><dt>2. </dt><dd><div id="nf2.TF.1.2"><p class="no_margin">See <a href="#nf2.Molecular_Genetics">Molecular Genetics</a> for information on allelic variants detected in this <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>.</p></div></dd><dt>3. </dt><dd><div id="nf2.TF.1.3"><p class="no_margin">Sequence analysis detects variants that are benign, likely benign, of <a class="def" href="/books/n/gene/glossary/def-item/uncertain-significance/">uncertain significance</a>, likely pathogenic, or pathogenic. Pathogenic variants may include small intragenic deletions/insertions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants; typically, <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> or whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions/duplications are not detected. For issues to consider in interpretation of <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a> results, click <a href="/books/n/gene/app2/">here</a>.</p></div></dd><dt>4. </dt><dd><div id="nf2.TF.1.4"><p class="no_margin"><a class="bk_pop" href="#nf2.REF.halliday.2017.657">Halliday et al [2017]</a></p></div></dd><dt>5. </dt><dd><div id="nf2.TF.1.5"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion-duplication-analysis/">deletion/duplication analysis</a> detects intragenic deletions or duplications. Methods used may include: <a class="def" href="/books/n/gene/glossary/def-item/quantitative-pcr/">quantitative PCR</a>, long-range PCR, multiplex ligation-dependent probe amplification (MLPA), and a <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>-targeted microarray designed to detect single-<a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> deletions or duplications.</p></div></dd><dt>6. </dt><dd><div id="nf2.TF.1.6"><p class="no_margin">Gene-targeted <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> testing will detect deletions ranging from a single <a class="def" href="/books/n/gene/glossary/def-item/exon/">exon</a> to the whole <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>; however, breakpoints of large deletions and/or deletion of adjacent genes may not be detected by these methods.</p></div></dd><dt>7. </dt><dd><div id="nf2.TF.1.7"><p class="no_margin">Chromosomal microarray analysis (CMA) uses oligonucleotide or SNP arrays to detect genome-wide large deletions/duplications (including <i>NF2</i>) that cannot be detected by <a class="def" href="/books/n/gene/glossary/def-item/sequence-analysis/">sequence analysis</a>. The ability to determine the size of the <a class="def" href="/books/n/gene/glossary/def-item/deletion/">deletion</a>/<a class="def" href="/books/n/gene/glossary/def-item/duplication/">duplication</a> depends on the type of microarray used and the density of probes in the 22q12.2 region. CMA designs in current clinical use target the 22q12.2 region.</p></div></dd><dt>8. </dt><dd><div id="nf2.TF.1.8"><p class="no_margin"><a class="bk_pop" href="#nf2.REF.smith.2016.250">Smith et al [2016]</a></p></div></dd></dl></div></div></div><p><b>Testing for <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a>.</b> Somatic mosaicism is frequent in NF2. As many as 25% to 33% of individuals with a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic <i>NF2</i> variant have somatic mosaicism for the variant [<a class="bk_pop" href="#nf2.REF.kluwe.2003.109">Kluwe et al 2003</a>, <a class="bk_pop" href="#nf2.REF.mohyuddin.2003.459">Mohyuddin et al 2003</a>, <a class="bk_pop" href="#nf2.REF.evans.2007b.424">Evans et al 2007b</a>, <a class="bk_pop" href="#nf2.REF.evans.2013.594">Evans et al 2013</a>].</p><p>Such individuals may have normal <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of <i>NF2</i> in unaffected tissue, such as lymphocytes; thus, molecular genetic testing of tumor tissue may be necessary to establish the presence of <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> [<a class="bk_pop" href="#nf2.REF.mohyuddin.2002.315">Mohyuddin et al 2002</a>, <a class="bk_pop" href="#nf2.REF.evans.2007b.424">Evans et al 2007b</a>].</p><p>When tumor DNA is tested, pathogenic variants in both <i>NF2</i> alleles must be identified:</p><ul><li class="half_rhythm"><div>This may mean testing for loss (or inactivation) of one <i>NF2</i> <a class="def" href="/books/n/gene/glossary/def-item/allele/">allele</a> by assessing for <a class="def" href="/books/n/gene/glossary/def-item/loss-of-heterozygosity/">loss of heterozygosity</a>.</div></li><li class="half_rhythm"><div>Once both variant <i>NF2</i> alleles are identified in the tumor, leukocyte DNA can be tested to determine which of the pathogenic variants is constitutional and which is somatic (i.e., present in the tumor only).</div></li></ul></div></div></div><div id="nf2.Clinical_Characteristics"><h2 id="_nf2_Clinical_Characteristics_">Clinical Characteristics</h2><div id="nf2.Clinical_Description"><h3>Clinical Description</h3><p>The average age of onset of findings in individuals with neurofibromatosis 2 (NF2) is 18 to 24 years (onset range: birth to 70 years). Almost all <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals develop bilateral vestibular schwannomas by age 30 years. In addition to vestibular schwannoma, individuals with NF2 develop schwannomas of other cranial and peripheral nerves, meningiomas, ependymomas, and (very rarely) astrocytomas.</p><p>Variable expressivity of NF2 among individuals results in varying size, location, and number of tumors. Although these tumors are not malignant, their anatomic location and multiplicity lead to great morbidity and early mortality. The average age of death is 36 years. Actuarial survival from the time of establishing the correct diagnosis is 15 years. Survival is improving with earlier diagnosis and better treatment in specialty centers [<a class="bk_pop" href="#nf2.REF.baser.2002.715">Baser et al 2002</a>, <a class="bk_pop" href="#nf2.REF.evans.2005a.5">Evans et al 2005a</a>, <a class="bk_pop" href="#nf2.REF.hexter.2015.699">Hexter et al 2015</a>].</p><p>Because NF2 is considered an adult-onset disease, it may be underrecognized in children, in whom skin tumors and ocular findings may be the first manifestations [<a class="bk_pop" href="#nf2.REF.evans.1999.496">Evans et al 1999</a>, <a class="bk_pop" href="#nf2.REF.ruggieri.2005.21">Ruggieri et al 2005</a>, <a class="bk_pop" href="#nf2.REF.ruggieri.2016.345">Ruggieri et al 2016</a>].</p><p>The presenting symptoms of 120 individuals with NF2 studied by <a class="bk_pop" href="#nf2.REF.evans.1992.603">Evans et al [1992]</a> in Great Britain are listed in <a class="figpopup" href="/books/NBK1201/table/nf2.T.presenting_symptoms_of_120_individ/?report=objectonly" target="object" rid-figpopup="fignf2Tpresentingsymptomsof120individ" rid-ob="figobnf2Tpresentingsymptomsof120individ">Table 2</a>. Although individuals in this study were mostly adults, some children were included. The study did not include as a first symptom skin tumors or cataracts, either of which may be the earliest finding in children.</p><div id="nf2.T.presenting_symptoms_of_120_individ" class="table"><h3><span class="label">Table 2. </span></h3><div class="caption"><p>Presenting Symptoms of 120 Individuals with NF2</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1201/table/nf2.T.presenting_symptoms_of_120_individ/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__nf2.T.presenting_symptoms_of_120_individ_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Symptom</th><th id="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">% of Affected Individuals</th></tr></thead><tbody><tr><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unilateral hearing loss</td><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">35%</td></tr><tr><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Focal weakness&#x000a0;<sup>1</sup></td><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">12%</td></tr><tr><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Tinnitus</td><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">10%</td></tr><tr><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Bilateral hearing loss</td><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">9%</td></tr><tr><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Balance dysfunction</td><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8%</td></tr><tr><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Seizure</td><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">8%</td></tr><tr><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Focal sensory loss</td><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">6%</td></tr><tr><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Blindness</td><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">1%</td></tr><tr><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No symptom, but detected on screening because a parent was <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a></td><td headers="hd_h_nf2.T.presenting_symptoms_of_120_individ_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">11%</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">Adapted from <a class="bk_pop" href="#nf2.REF.evans.1992.603">Evans et al [1992]</a></p></div></dd><dt>1. </dt><dd><div id="nf2.TF.2.1"><p class="no_margin">Can result from spinal tumors, mononeuropathy, or polyneuropathy</p></div></dd></dl></div></div></div><div id="nf2.Presenting_Features_of_NF2_in_Childh"><h4>Presenting Features of NF2 in Childhood</h4><p><b>Skin</b> findings include intradermal plaque-like tumors that often have excess hair and skin pigmentation.</p><p><b>Ocular</b> findings include [<a class="bk_pop" href="#nf2.REF.evans.2005a.5">Evans et al 2005a</a>, <a class="bk_pop" href="#nf2.REF.feucht.2008.882">Feucht et al 2008</a>, <a class="bk_pop" href="#nf2.REF.ruggieri.2016.345">Ruggieri et al 2016</a>]:</p><ul><li class="half_rhythm"><div>Retinal hamartoma</div></li><li class="half_rhythm"><div>Thickened optic nerves</div></li><li class="half_rhythm"><div>Cortical wedge cataracts that may be <a class="def" href="/books/n/gene/glossary/def-item/congenital/">congenital</a> and associated with amblyopia</div></li><li class="half_rhythm"><div>Third cranial nerve palsy</div></li></ul><p><b>Other</b></p><ul><li class="half_rhythm"><div>A mononeuropathy (e.g., a facial nerve palsy, foot or wrist drop) with no obvious tumor cause</div></li><li class="half_rhythm"><div>An <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> meningioma, or a schwannoma at any site [<a class="bk_pop" href="#nf2.REF.evans.1999.496">Evans et al 1999</a>, <a class="bk_pop" href="#nf2.REF.perry.2001.994">Perry et al 2001</a>, <a class="bk_pop" href="#nf2.REF.pathmanaban.2017.1123">Pathmanaban et al 2017</a>]</div></li></ul></div><div id="nf2.Details_of_Typical_Clinical_Findings"><h4>Details of Typical Clinical Findings in NF2</h4><p><b>Vestibular schwannoma.</b> Initial symptoms include tinnitus, hearing loss, and balance dysfunction. Onset of disability is usually insidious, although occasionally hearing loss may occur suddenly, presumably as a result of vascular compromise by the tumor. Affected individuals often report difficulty in using the telephone in one ear or unsteadiness when walking at night or on uneven ground.</p><p>With time, vestibular tumors extend medially into the cerebellar pontine angle and, if left untreated, cause compression of the brain stem and hydrocephalus. Significant facial palsy is rare even in large tumors.</p><p>Schwannomas may also develop on other cranial and peripheral nerves, with sensory nerves more frequently affected than motor nerves.</p><p>Children and young adults with an apparently <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> vestibular or other cranial nerve schwannoma should be considered at risk for <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> and often mosaic NF2 [<a class="bk_pop" href="#nf2.REF.pathmanaban.2017.1123">Pathmanaban et al 2017</a>].</p><p><b>Spinal tumors.</b> At least two thirds of individuals with NF2 develop spinal tumors, which are often the most devastating and difficult to manage [<a class="bk_pop" href="#nf2.REF.dow.2005.574">Dow et al 2005</a>]. The most common spinal tumors are schwannomas, which usually originate within the intravertebral canal on the dorsal root and extend both medially and laterally, taking the shape of a "dumbbell." Intramedullary tumors of the spinal cord, such as astrocytoma and ependymoma, occur in 5% to 33% of individuals with NF2. Most persons with spinal cord involvement have multiple tumors. Although multiple tumors are often present on imaging studies, they remain asymptomatic in many individuals.</p><p><b>Meningioma.</b> Approximately half of individuals with NF2 have meningiomas in cross-sectional studies [<a class="bk_pop" href="#nf2.REF.goutagny.2010.341">Goutagny &#x00026; Kalamarides 2010</a>]; however, lifetime risk may approach 80% [<a class="bk_pop" href="#nf2.REF.smith.2011.261">Smith et al 2011</a>]. Most are intracranial, although spinal meningiomas occur. NF2 meningiomas tend to occur less frequently in the skull base than supratentorially and are usually of the fibroblastic variety [<a class="bk_pop" href="#nf2.REF.evans.2000.897">Evans et al 2000</a>, <a class="bk_pop" href="#nf2.REF.kros.2001.367">Kros et al 2001</a>]. Meningiomas in the orbit may compress the optic nerve and result in visual loss. Those at the skull base may cause cranial neuropathy, brain stem compression, and hydrocephalus.</p><p>See <a href="#nf2.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</p><p><b>Ocular involvement.</b> One third of individuals with NF2 have decreased visual acuity in one or both eyes. Posterior subcapsular lens opacity &#x02013; rarely progressing to a visually significant cataract &#x02013; is the most common ocular finding. Lens opacities may appear prior to the onset of symptoms from vestibular schwannoma and can be seen in children.</p><p>Retinal hamartoma and epiretinal membrane are seen in up to one third of individuals. Rarely, other ocular manifestations may occur: persistent hyperplastic primary vitreous has been reported in a father and son [<a class="bk_pop" href="#nf2.REF.nguyen.2005.247">Nguyen et al 2005</a>]. In adulthood, particular problems with the cornea can occur especially after surgery, resulting in the loss of facial, trigeminal, and intermedius nerve function.</p><p>Intracranial and intraorbital tumors may result in decreased visual acuity and diplopia.</p><p><b>Mono-/polyneuropathy.</b> A recognized feature of NF2 is a mononeuropathy occurring particularly in childhood [<a class="bk_pop" href="#nf2.REF.evans.1999.496">Evans et al 1999</a>] and frequently presenting as a facial palsy that usually only partially recovers, a squint (3rd nerve palsy), or a foot or hand drop. The foot drop may mimic polio.</p><p>A progressive polyneuropathy of adulthood not directly related to tumor masses is also recognized [<a class="bk_pop" href="#nf2.REF.sperfeld.2002.996">Sperfeld et al 2002</a>].</p><p>Further evidence for the mononeuropathy of childhood and the polyneuropathy of adulthood has come from sural nerve biopsies [<a class="bk_pop" href="#nf2.REF.hagel.2002.179">Hagel et al 2002</a>].</p><p><b>Other.</b> Renal vascular disease similar to that occurring in neurofibromatosis type 1 (NF1) has been reported once [<a class="bk_pop" href="#nf2.REF.cordeiro.2006.58">Cordeiro et al 2006</a>], but may be coincidental as it has not been reported again.</p><p><b>Somatic <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> for pathogenic variants in <i>NF2</i>.</b> Mosaicism has been suspected in individuals with unilateral vestibular schwannoma and multiple other, often ipsilateral, tumors [<a class="bk_pop" href="#nf2.REF.mohyuddin.2003.459">Mohyuddin et al 2003</a>, <a class="bk_pop" href="#nf2.REF.evans.2008.92">Evans et al 2008</a>]. This has now been confirmed for most cases in which DNA from multiple tumors has been analyzed [<a class="bk_pop" href="#nf2.REF.mohyuddin.2003.459">Mohyuddin et al 2003</a>, <a class="bk_pop" href="#nf2.REF.wallace.2004.368">Wallace et al 2004</a>, <a class="bk_pop" href="#nf2.REF.aghi.2006.201">Aghi et al 2006</a>, <a class="bk_pop" href="#nf2.REF.evans.2008.92">Evans et al 2008</a>].</p><p><b>Histopathology.</b> The tumors of NF2 are derived from Schwann cells, meningeal cells, and glial cells. They are uniformly benign. Approximately 40% of NF2 vestibular tumors have a lobular pattern that is uncommon in tumors from individuals without a diagnosis of NF2.</p><ul><li class="half_rhythm"><div>NF2-associated vestibular schwannomas tend to be more invasive and to have a higher degree of dividing cells than non-NF2 tumors.</div></li><li class="half_rhythm"><div>NF2-associated meningiomas have a higher degree of dividing cells than non-NF2 meningiomas. NF2 meningiomas are usually of the fibroblastic variety.</div></li><li class="half_rhythm"><div>No histologic differences have been observed between glial tumors in individuals with NF2 and individuals who do not have NF2.</div></li></ul></div></div><div id="nf2.GenotypePhenotype_Correlations"><h3>Genotype-Phenotype Correlations</h3><p>Intrafamilial variability is much lower than <a class="def" href="/books/n/gene/glossary/def-item/interfamilial-variability/">interfamilial variability</a>, suggesting a strong effect of the underlying <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a> on the resulting <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>.</p><p>Unlike <a href="/books/n/gene/nf1/">neurofibromatosis type 1</a> (NF1), large deletions of <i>NF2</i> have been associated with a mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#nf2.REF.baser.2004.231">Baser et al 2004</a>]; even if quite large, these deletions are not associated with intellectual disability.</p><p>The type of <i>NF2</i> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is an important determinant of the number of NF2-associated intracranial meningiomas, spinal tumors, and peripheral nerve tumors [<a class="bk_pop" href="#nf2.REF.baser.2004.231">Baser et al 2004</a>]:</p><ul><li class="half_rhythm"><div>Nonsense and frame-shifting variants have been associated with severe disease regardless of their position within the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#nf2.REF.baser.2004.231">Baser et al 2004</a>].</div></li><li class="half_rhythm"><div>Splice site variants have been associated with both mild and severe disease [<a class="bk_pop" href="#nf2.REF.kluwe.1998.228">Kluwe et al 1998</a>, <a class="bk_pop" href="#nf2.REF.baser.2005.540">Baser et al 2005</a>] and may be milder if occurring in the 3' half of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#nf2.REF.baser.2005.540">Baser et al 2005</a>].</div></li><li class="half_rhythm"><div>Missense variants are usually associated with a mild <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a>, often causing the mildest form of NF2 [<a class="bk_pop" href="#nf2.REF.evans.1998a.450">Evans et al 1998a</a>, <a class="bk_pop" href="#nf2.REF.baser.2002.715">Baser et al 2002</a>].</div></li><li class="half_rhythm"><div>Truncating variants are associated with earlier onset and greater number of NF2-associated intracranial meningiomas, spinal tumors, and peripheral nerve tumors. In general, truncating variants (frameshift and <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>) are associated with greater disease-related mortality than <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> and <a class="def" href="/books/n/gene/glossary/def-item/splice-site/">splice site</a> variants or deletions [<a class="bk_pop" href="#nf2.REF.baser.2002.715">Baser et al 2002</a>, <a class="bk_pop" href="#nf2.REF.baser.2005.540">Baser et al 2005</a>]. Truncating variants are also associated with increased prevalence of spinal tumors [<a class="bk_pop" href="#nf2.REF.patronas.2001.434">Patronas et al 2001</a>, <a class="bk_pop" href="#nf2.REF.dow.2005.574">Dow et al 2005</a>]. Although most of these pathogenic variants would be predicted to result in nonsense-mediated decay, and thus no protein product, the apparent <a class="def" href="/books/n/gene/glossary/def-item/dominant-negative/">dominant-negative</a> effect of these variants requires further investigation.</div></li><li class="half_rhythm"><div>Pathogenic variants in the 3' half of <i>NF2</i> (especially those in exons 14-16) are associated with lower risk of meningioma than pathogenic variants in the 5' half of the <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#nf2.REF.smith.2011.261">Smith et al 2011</a>] (see <a class="figpopup" href="/books/NBK1201/figure/nf2.F1/?report=objectonly" target="object" rid-figpopup="fignf2F1" rid-ob="figobnf2F1">Figure 1</a>).</div></li></ul><div class="iconblock whole_rhythm clearfix ten_col fig" id="fignf2F1" co-legend-rid="figlgndnf2F1"><a href="/books/NBK1201/figure/nf2.F1/?report=objectonly" target="object" title="Figure 1. " class="img_link icnblk_img figpopup" rid-figpopup="fignf2F1" rid-ob="figobnf2F1"><img class="small-thumb" src="/books/NBK1201/bin/nf2-Image001.gif" src-large="/books/NBK1201/bin/nf2-Image001.jpg" alt="Figure 1. . The position of pathogenic variants in NF2 affects the likelihood of developing a meningioma." /></a><div class="icnblk_cntnt" id="figlgndnf2F1"><h4 id="nf2.F1"><a href="/books/NBK1201/figure/nf2.F1/?report=objectonly" target="object" rid-ob="figobnf2F1">Figure 1. </a></h4><p class="float-caption no_bottom_margin">The position of pathogenic variants in <i>NF2</i> affects the likelihood of developing a meningioma. A. The Kaplan-Meier plot shows the risk of meningioma within each functional domain. Gene regions are divided into exons 1-3, 4-6, 7-9, 10-13, and 14-15.</p></div></div><p>Somatic <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> (even when detected in lymphocyte DNA) for typical pathogenic truncating variants that would normally cause severe NF2 may result in a milder <a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> [<a class="bk_pop" href="#nf2.REF.evans.1998a.450">Evans et al 1998a</a>, <a class="bk_pop" href="#nf2.REF.evans.2007b.424">Evans et al 2007b</a>, <a class="bk_pop" href="#nf2.REF.evans.2013.594">Evans et al 2013</a>].</p></div><div id="nf2.Penetrance"><h3>Penetrance</h3><p>Penetrance is close to 100%. Virtually all individuals who have a <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> develop the disease in an average lifetime.</p><p>Age at onset can vary with variant type; see <a href="#nf2.GenotypePhenotype_Correlations">Genotype-Phenotype Correlations</a>.</p></div><div id="nf2.Nomenclature"><h3>Nomenclature</h3><p>The term "neurofibromatosis" is a misnomer because the primary tumor types in NF2 are schwannoma and meningioma. Vestibular schwannoma (previously termed "acoustic neuroma") was initially considered part of von Recklinghausen <a href="/books/n/gene/nf1/">neurofibromatosis type 1</a>, leading to multiple instances in which individuals with NF2 were included in series of individuals with NF1.</p><p>Since 1987, the great majority of reports have correctly distinguished between NF1 and NF2, with NF2 described as "bilateral acoustic" or "central" neurofibromatosis.</p></div><div id="nf2.Prevalence"><h3>Prevalence</h3><p>The estimated prevalence of NF2 is 1:60,000 [<a class="bk_pop" href="#nf2.REF.evans.2010.327">Evans et al 2010</a>], with a birth incidence of 1:33,000.</p><p>NF2 has no ethnic or racial predilections.</p></div></div><div id="nf2.Genetically_Related_Allelic_Disorder"><h2 id="_nf2_Genetically_Related_Allelic_Disorder_">Genetically Related (Allelic) Disorders</h2><p>No other phenotypes are known to be associated with pathogenic variants in <i>NF2</i>.</p></div><div id="nf2.Differential_Diagnosis"><h2 id="_nf2_Differential_Diagnosis_">Differential Diagnosis</h2><div id="nf2.T.disorders_to_consider_in_the_diffe" class="table"><h3><span class="label">Table 3. </span></h3><div class="caption"><p>Disorders to Consider in the Differential Diagnosis of NF2</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1201/table/nf2.T.disorders_to_consider_in_the_diffe/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__nf2.T.disorders_to_consider_in_the_diffe_lrgtbl__"><table class="no_bottom_margin"><thead><tr><th id="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_1" rowspan="2" scope="col" colspan="1" headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_1" style="text-align:left;vertical-align:middle;">Disorder</th><th id="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="2" scope="col" colspan="1" headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_2" style="text-align:left;vertical-align:middle;">Gene(s)</th><th id="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="2" scope="col" colspan="1" headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_3" style="text-align:left;vertical-align:middle;">MOI</th><th id="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_4" colspan="2" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Clinical Features of This Disorder</th></tr><tr><th headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_4" id="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_2_1" colspan="1" scope="colgroup" rowspan="1" style="text-align:left;vertical-align:middle;">Overlapping w/NF2</th><th headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_4" id="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_2_2" scope="col" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Distinguishing from NF2</th></tr></thead><tbody><tr><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/nf1/">Neurofibromatosis type 1</a></td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>NF1</i></td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Dumbbell configuration of spinal tumors</td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Intellectual/learning disability</div></li><li class="half_rhythm"><div>Lisch nodules</div></li><li class="half_rhythm"><div>Caf&#x000e9; au lait macules</div></li></ul>
</td></tr><tr><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/schwann/">Schwannomatosis 1</a></td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>SMARCB1</i></td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Multiple schwannomas</td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No vestibular schwannomas</td></tr><tr><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><a href="/books/n/gene/schwann/">Schwannomatosis 2</a></td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><i>LZTR1</i>&#x000a0;<sup>1</sup></td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">AD</td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unilateral vestibular schwanomma &#x00026; other schwannomas</td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No intradermal schwannoma plaques, cataract, or ependymoma</td></tr><tr><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Unilateral vestibular schwannoma&#x000a0;<sup>2</sup></td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">N/A</td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Vestibular schwannoma</td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;"><ul><li class="half_rhythm"><div>Schwannoma on one side only</div></li><li class="half_rhythm"><div>No underlying predisposition to vestibular schwannomas</div></li></ul>
</td></tr><tr><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_1" scope="row" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Meningioma&#x000a0;<sup>3</sup></td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Typically N/A; rarely <i>SMARCB1</i>&#x000a0;<sup>4</sup></td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_3" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Rarely AD</td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_2_1" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">Multiple meningiomas</td><td headers="hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_1_4 hd_h_nf2.T.disorders_to_consider_in_the_diffe_1_1_2_2" rowspan="1" colspan="1" style="text-align:left;vertical-align:middle;">No vestibular schwannomas</td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div><p class="no_margin">AD = <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a>; MOI = <a class="def" href="/books/n/gene/glossary/def-item/mode-of-inheritance/">mode of inheritance</a>; N/A = not applicable</p></div></dd><dt>1. </dt><dd><div id="nf2.TF.3.1"><p class="no_margin"><a class="bk_pop" href="#nf2.REF.smith.2017.87">Smith et al [2017]</a> found that for individuals with a unilateral vestibular schwannoma and additional non-intradermal schwannomas, a constitutional <i>LZTR1</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is a significant possibility.</p></div></dd><dt>2. </dt><dd><div id="nf2.TF.3.2"><p class="no_margin">The risk that a unilateral tumor is the first manifestation of NF2 is closely related to the age of the <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual. Individuals younger than age 30 years with a symptomatic unilateral vestibular schwannoma are at high risk of developing a contralateral tumor and NF2 and should be monitored closely, while individuals older than age 30 years who have a unilateral vestibular schwannoma are at very low risk of developing NF2 [<a class="bk_pop" href="#nf2.REF.evans.2007a.354">Evans et al 2007a</a>].</p></div></dd><dt>3. </dt><dd><div id="nf2.TF.3.3"><p class="no_margin">Multiple meningiomas typically occur in older adults; thus, the finding of a single meningioma in an individual younger than age 25 years should prompt evaluation for an underlying genetic condition [<a class="bk_pop" href="#nf2.REF.evans.2005b.45">Evans et al 2005b</a>].</p></div></dd><dt>4. </dt><dd><div id="nf2.TF.3.4"><p class="no_margin">A <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in <i>SMARCB1</i> was found to be responsible for schwannomatosis in several members of one family [<a class="bk_pop" href="#nf2.REF.christiaans.2011.93">Christiaans et al 2011</a>]; however, the great majority of individuals with multiple meningiomas do not harbor a <i>SMARCB1</i> pathogenic variant [<a class="bk_pop" href="#nf2.REF.hadfield.2010.567">Hadfield et al 2010</a>].</p></div></dd></dl></div></div></div></div><div id="nf2.Management"><h2 id="_nf2_Management_">Management</h2><div id="nf2.Evaluations_Following_Initial_Diagno"><h3>Evaluations Following Initial Diagnosis</h3><p>To establish the extent of disease and needs in an individual diagnosed with neurofibromatosis 2 (NF2), the following are recommended if they have not already been completed:</p><ul><li class="half_rhythm"><div>Head MRI</div></li><li class="half_rhythm"><div>Hearing evaluation, including brain stem auditory evoked response (BAER)</div></li><li class="half_rhythm"><div>Ophthalmologic evaluation</div></li><li class="half_rhythm"><div>Cutaneous examination</div></li><li class="half_rhythm"><div>Consultation with a clinical geneticist and/or genetic counselor</div></li></ul><p>Note: Evaluation and treatment of individuals with neurofibromatosis 2 (NF2) are best undertaken in an NF2 center experienced in managing the multiple complications of the disease [<a class="bk_pop" href="#nf2.REF.baser.2002.715">Baser et al 2002</a>, <a class="bk_pop" href="#nf2.REF.evans.2005a.5">Evans et al 2005a</a>].</p><ul><li class="half_rhythm"><div>For NF specialists see <a href="http://www.ctf.org/understanding-nf/find-doctor" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ctf.org</a>.</div></li><li class="half_rhythm"><div>For NF2 service centers in the UK see <a href="https://nervetumours.org.uk/what-are-nerve-tumours/what-is-nf2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nfauk.org</a>.</div></li></ul></div><div id="nf2.Treatment_of_Manifestations"><h3>Treatment of Manifestations</h3><p><b>Vestibular schwannoma.</b> Untreated tumors may be slow growing and not require active intervention in the short term [<a class="bk_pop" href="#nf2.REF.masuda.2004.150">Masuda et al 2004</a>, <a class="bk_pop" href="#nf2.REF.slattery.2004.811">Slattery et al 2004</a>]. Therapy remains primarily surgical.</p><ul><li class="half_rhythm"><div>Small vestibular tumors (&#x0003c;1.5 mm) that are completely intercanalicular can often be completely resected, with preservation of both hearing and facial nerve function.</div></li><li class="half_rhythm"><div>Larger tumors are probably best managed expectantly, with debulking or decompression carried out only when brain stem compression, deterioration of hearing, and/or facial nerve dysfunction occur [<a class="bk_pop" href="#nf2.REF.evans.2005a.5">Evans et al 2005a</a>]. However, balancing between early surgery and preservation of facial function and later surgery when an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual is still hearing is difficult [<a class="bk_pop" href="#nf2.REF.evans.2005a.5">Evans et al 2005a</a>].</div></li></ul><p>Stereotactic radiosurgery, most commonly with the gamma knife, has been offered as an alternative to surgery in select individuals with vestibular schwannoma. However, the outcomes from radiation treatment in individuals with NF2 are not as good as for individuals with <a class="def" href="/books/n/gene/glossary/def-item/sporadic/">sporadic</a> unilateral vestibular schwannoma, with only approximately 60% long-term tumor control [<a class="bk_pop" href="#nf2.REF.rowe.2003.1288">Rowe et al 2003</a>, <a class="bk_pop" href="#nf2.REF.chung.2018.47">Chung et al 2018</a>].</p><p>Malignant transformation is a possible (though probably not common) sequela [<a class="bk_pop" href="#nf2.REF.baser.2000.998">Baser et al 2000</a>]; however, it should be noted that tumor development following radiation may take 15 years [<a class="bk_pop" href="#nf2.REF.evans.2006.289">Evans et al 2006</a>]. This may involve development of a malignancy within the treated lesion or a new malignancy (e.g., glioblastoma) in the radiation field [<a class="bk_pop" href="#nf2.REF.balasubramaniam.2007.447">Balasubramaniam et al 2007</a>, <a class="bk_pop" href="#nf2.REF.halliday.2018.29">Halliday et al 2018</a>].</p><p>More recently, treatment with the VEGF antibody bevacizumab has shown promise in the treatment of rapidly growing vestibular schwannomas, with some individuals regaining hearing [<a class="bk_pop" href="#nf2.REF.plotkin.2009.358">Plotkin et al 2009</a>, <a class="bk_pop" href="#nf2.REF.morris.2016.281">Morris et al 2016</a>, <a class="bk_pop" href="#nf2.REF.halliday.2018.29">Halliday et al 2018</a>]. Response to treatment occurs in about 60%-70% of individuals; treatment can be sustained over years but with some concerns over renal toxicity [<a class="bk_pop" href="#nf2.REF.slusarz.2014.1197">Slusarz et al 2014</a>, <a class="bk_pop" href="#nf2.REF.morris.2016.281">Morris et al 2016</a>, <a class="bk_pop" href="#nf2.REF.halliday.2018.29">Halliday et al 2018</a>].</p><p>Management of individuals with vestibular tumors should include counseling for insidious problems with balance and underwater disorientation, which can result in drowning.</p><p><b>Other tumors.</b> Other intracranial, cranial nerve, or spinal nerve tumors are very slow growing, and surgical intervention for a tumor producing little impairment may cause disability years before it would occur naturally.</p><p>Although ependymoma in individuals without NF2 is optimally treated with complete resection, and occasionally with radiotherapy and chemotherapy, it is unclear whether ependymoma in individuals with NF2 warrants aggressive management. However, bevacizumab has shown some clinical benefit in some individuals [<a class="bk_pop" href="#nf2.REF.farschtschi.2016.475">Farschtschi et al 2016</a>, <a class="bk_pop" href="#nf2.REF.morris.2017.474">Morris et al 2017</a>].</p><p>Use of radiation therapy for NF2-associated tumors should be carefully considered because radiation exposure may induce, accelerate, or transform tumors in an individual (especially a child) with an inactive tumor suppressor <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> [<a class="bk_pop" href="#nf2.REF.baser.2000.998">Baser et al 2000</a>, <a class="bk_pop" href="#nf2.REF.evans.2006.289">Evans et al 2006</a>].</p><p><b>Hearing.</b> Hearing preservation and augmentation are important in the management of individuals with NF2. All <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals and their families should be referred to an audiologist to receive training in optimization of hearing and speech production.</p><ul><li class="half_rhythm"><div>Lip-reading skills may be enhanced by instruction.</div></li><li class="half_rhythm"><div>Sign language may often be more effectively acquired before the individual loses hearing.</div></li><li class="half_rhythm"><div>Hearing aids may be helpful early in the course of the disease [<a class="bk_pop" href="#nf2.REF.evans.2005a.5">Evans et al 2005a</a>].</div></li><li class="half_rhythm"><div>Auditory rehabilitation with a cochlear or brain stem implant should be discussed with those who have lost hearing [<a class="bk_pop" href="#nf2.REF.evans.2005a.5">Evans et al 2005a</a>]. Rarely, individuals who have had vascular insult to the cochlea, but otherwise are without nerve damage, may benefit from a cochlear implant. Implants can also be used in stable tumors where hearing has been lost but there is evidence of cochlear nerve function [<a class="bk_pop" href="#nf2.REF.north.2016.172">North et al 2016</a>]</div></li></ul><p><b>Ocular involvement.</b> Early recognition and management of visual impairment from other manifestations of NF2 are extremely important. Most NF2-associated cataracts do not require removal, but particular attention should be paid to cataracts in infancy that may affect vision by causing amblyopia. These may require removal and patching of the unaffected eye.</p><p><b>Cutaneous involvement.</b> While removal of cutaneous schwannomas is not required, it may be indicated if the schwannomas are causing disfigurement or pain. Removal may also help diagnostically.</p></div><div id="nf2.Prevention_of_Secondary_Complication"><h3>Prevention of Secondary Complications</h3><p>Treatment concentrates on prevention of secondary complications. Prevention of substantial handicap from the disease can be achieved by appropriate expert treatment of tumors:</p><ul><li class="half_rhythm"><div>A cervical spinal scan should be performed before cranial surgery to prevent complications from manipulation under anesthesia [<a class="bk_pop" href="#nf2.REF.evans.2005a.5">Evans et al 2005a</a>].</div></li><li class="half_rhythm"><div>Spinal tumors may make epidural analgesia difficult; therefore, lumbosacral imaging should be performed before regional analgesia is given [<a class="bk_pop" href="#nf2.REF.sakai.2005.332">Sakai et al 2005</a>, <a class="bk_pop" href="#nf2.REF.spiegel.2005.336">Spiegel et al 2005</a>].</div></li></ul></div><div id="nf2.Surveillance"><h3>Surveillance</h3><p>For at-risk individuals (1) in whom the known <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> in the family has been identified or (2) whose genetic status cannot be clarified by <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a>:</p><ul><li class="half_rhythm"><div><b>MRI</b> is usually begun between ages ten and 12 years but can be delayed in families in which the onset is known to be later [<a class="bk_pop" href="#nf2.REF.evans.2005a.5">Evans et al 2005a</a>]. MRI should be continued on an annual basis until at least the fourth decade of life. It is not clear if earlier surveillance (i.e., cranial MRI before age 10 years) is beneficial, and it is not known at what age monitoring can be safely stopped. Although some individuals with NF2 do not have symptoms until they are in their fifties, it is likely that "silent" tumors would be detected on an MRI performed at a younger age.</div></li><li class="half_rhythm"><div><b>Hearing evaluation,</b> including BAER testing, may be useful in detecting changes in auditory nerve function before changes can be visualized by MRI.</div></li><li class="half_rhythm"><div><b>Complete eye examinations</b> should be part of the care of all individuals with NF2 and ideally should be conducted annually.</div></li></ul></div><div id="nf2.AgentsCircumstances_to_Avoid"><h3>Agents/Circumstances to Avoid</h3><p>Radiotherapy for NF2 should be avoided in childhood, when malignancy risks are likely to be substantially larger [<a class="bk_pop" href="#nf2.REF.evans.2006.289">Evans et al 2006</a>].</p></div><div id="nf2.Evaluation_of_Relatives_at_Risk"><h3>Evaluation of Relatives at Risk</h3><p>It is appropriate to clarify the genetic status of apparently asymptomatic older and younger sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and other at-risk relatives in order to identify as early as possible those who would benefit from prompt initiation of appropriate screening (see <a href="#nf2.Surveillance">Surveillance</a>), thus resulting in earlier detection of disease manifestations and improved final outcomes [<a class="bk_pop" href="#nf2.REF.evans.2005a.5">Evans et al 2005a</a>].</p><p>Note: Tumor testing can identify both mutational hits in the majority of cases of <a class="def" href="/books/n/gene/glossary/def-item/isolated/">isolated</a> NF2 and allow exclusion testing in sibs and other at-risk relatives.</p><p>See <a href="#nf2.Related_Genetic_Counseling_Issues">Genetic Counseling</a> for issues related to testing of at-risk relatives for <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> purposes.</p></div><div id="nf2.Pregnancy_Management"><h3>Pregnancy Management</h3><p>Although there is no convincing evidence that schwannomas increase in size during pregnancy, hormonal effects on meningiomas are possible; therefore, assessment of the potential risk of increased intracranial pressure is important for women considering pregnancy.</p></div><div id="nf2.Therapies_Under_Investigation"><h3>Therapies Under Investigation</h3><p>Search <a href="http://clinicaltrials.gov/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">ClinicalTrials.gov</a> in the US and <a href="http://www.ClinicalTrialsRegister.eu" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ClinicalTrialsRegister.eu</a> in Europe for information on clinical studies for a wide range of diseases and conditions.</p></div></div><div id="nf2.Genetic_Counseling"><h2 id="_nf2_Genetic_Counseling_">Genetic Counseling</h2><p>
<i>Genetic counseling is the process of providing individuals and families with
information on the nature, inheritance, and implications of genetic disorders to help them
make informed medical and personal decisions. The following section deals with genetic
risk assessment and the use of family history and genetic testing to clarify genetic
status for family members. This section is not meant to address all personal, cultural, or
ethical issues that individuals may face or to substitute for consultation with a genetics
professional</i>. &#x02014;ED.</p><div id="nf2.Mode_of_Inheritance"><h3>Mode of Inheritance</h3><p>Neurofibromatosis 2 (NF2) is inherited in an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> manner.</p></div><div id="nf2.Risk_to_Family_Members"><h3>Risk to Family Members</h3><p><b>Parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div class="half_rhythm">Approximately 50% of individuals diagnosed with NF2 have an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> parent. While there is a strong <a class="def" href="/books/n/gene/glossary/def-item/genotype/">genotype</a>-<a class="def" href="/books/n/gene/glossary/def-item/phenotype/">phenotype</a> correlation, significant variability within families and even between identical twins can be seen.</div></li><li class="half_rhythm"><div class="half_rhythm">Approximately 50% of individuals diagnosed with NF2 have the disorder as the result of a <i>de novo NF2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div><div class="half_rhythm">25% to 33% of individuals who are <a class="def" href="/books/n/gene/glossary/def-item/simplex/">simplex</a> cases (i.e., individuals with no family history of NF2) are mosaic for an <i>NF2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> [<a class="bk_pop" href="#nf2.REF.kluwe.2003.109">Kluwe et al 2003</a>, <a class="bk_pop" href="#nf2.REF.mohyuddin.2003.459">Mohyuddin et al 2003</a>, <a class="bk_pop" href="#nf2.REF.evans.2007b.424">Evans et al 2007b</a>, <a class="bk_pop" href="#nf2.REF.evans.2013.594">Evans et al 2013</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">Molecular genetic testing is recommended for the parents of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div class="half_rhythm">If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in leukocyte DNA of either parent, possible explanations include a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> pathogenic variant in the proband or <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a> in a parent. The incidence of pure germline mosaicism in NF2 is extremely low as thus far all parents having more than one <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child have had a detectable pathogenic variant in NF2 in blood DNA and have been clinically affected [<a class="bk_pop" href="#nf2.REF.evans.2013.594">Evans et al 2013</a>]. There is one historical case of two affected children born to apparently unaffected parents before <i>NF2</i> testing was available [<a class="bk_pop" href="#nf2.REF.parry.1996.529">Parry et al 1996</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">The family history of some individuals diagnosed with NF2 may appear to be negative because of failure to recognize the disorder in family members or early death of the parent before the onset of symptoms. Therefore, an apparently negative family history cannot be confirmed unless <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> has been performed on the parents of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</div></li><li class="half_rhythm"><div class="half_rhythm">The possibility that a parent has NF2 can be excluded if his/her offspring is shown to be mosaic, but absence of a <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> does not eliminate the possibility of <a class="def" href="/books/n/gene/glossary/def-item/mosaicism/">mosaicism</a> in the parent. Because the age of onset of symptoms is consistent within families, it is usually not necessary to offer surveillance to asymptomatic parents.</div></li><li class="half_rhythm"><div class="half_rhythm">If the parent is the individual in whom the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> first occurred, s/he may have <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for the variant and may be mildly/minimally <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>.</div></li></ul><p><b>Sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a></b></p><ul><li class="half_rhythm"><div>The risk to the sibs of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> depends on the genetic status of the parents.</div></li><li class="half_rhythm"><div>If a parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, the risk to the sibs is 50%.</div></li><li class="half_rhythm"><div>If the parents have been tested for the <i>NF2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> identified in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> and:</div><ul><li class="half_rhythm"><div>One parent of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has the <i>NF2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>, the risk to the sibs of inheriting the variant is 50%. The age of onset of symptoms within a family is relatively consistent.</div></li><li class="half_rhythm"><div>The <i>NF2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> found in the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> cannot be detected in the leukocyte DNA of either parent, the risk to sibs is slightly greater than that of the general population because of the possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>. A single case of germline mosaicism in a clinically normal parent has been reported [<a class="bk_pop" href="#nf2.REF.parry.1994.450">Parry et al 1994</a>].</div></li></ul></li><li class="half_rhythm"><div>If the parents have not been tested for the <i>NF2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> but are clinically unaffected, the risk to the sibs of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> appears to be low. The sibs of a proband with clinically unaffected parents are still at increased risk for NF2 because of the possibility of parental <a class="def" href="/books/n/gene/glossary/def-item/germline-mosaicism/">germline mosaicism</a>.</div></li></ul><p><b>Offspring of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>.</b> Each child of an individual with NF2 has up to a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>:</p><ul><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> has other <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> family members, each child of the proband has a 50% chance of inheriting the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</div></li><li class="half_rhythm"><div>If the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> is the only <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individual in the family, two possibilities exist:</div><ul><li class="half_rhythm"><div class="half_rhythm">The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> may have <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> for the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Offspring of an individual who is mosaic may have a less than 50% risk of inheriting the pathogenic variant.</div><div class="half_rhythm">Persons with <a class="def" href="/books/n/gene/glossary/def-item/somatic-mosaicism/">somatic mosaicism</a> and bilateral vestibular tumors have a less than 50% chance of having an <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> child [<a class="bk_pop" href="#nf2.REF.evans.1998b.727">Evans et al 1998b</a>]. If the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> is detected in DNA from multiple tumors, but not in DNA from leukocytes, the risk to offspring is probably less than 5% [<a class="bk_pop" href="#nf2.REF.evans.2009.5032">Evans et al 2009</a>].</div></li><li class="half_rhythm"><div class="half_rhythm">The <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> may have a <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> (i.e., present in the egg or sperm at the time of conception). Each offspring of an individual with a <i>de novo</i> germline pathogenic variant has a 50% chance of inheriting the variant.</div></li></ul></li></ul><p><b>Other family members.</b> The risk to other family members depends on the genetic status of the <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a>'s parents: if a parent is <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a>, his or her family members may be at risk.</p></div><div id="nf2.Related_Genetic_Counseling_Issues"><h3>Related Genetic Counseling Issues</h3><p>See Management, <a href="#nf2.Evaluation_of_Relatives_at_Risk">Evaluation of Relatives at Risk</a> for information on evaluating at-risk relatives for the purpose of early diagnosis and treatment.</p><p><b>Testing of at-risk asymptomatic family members.</b> Consideration of <a class="def" href="/books/n/gene/glossary/def-item/molecular-genetic-testing/">molecular genetic testing</a> of at-risk family members during childhood is appropriate for surveillance (see <a href="#nf2.Surveillance">Surveillance</a>).</p><p>Because early detection of at-risk individuals affects medical management, testing of at-risk asymptomatic individuals younger than age 18 years is beneficial. Parents often want to know the genetic status of their children prior to initiating screening in order to avoid unnecessary procedures for a child who has not inherited the <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>. Special consideration should be given to education of the children and their parents prior to genetic testing. A plan should be established for the manner in which results are to be given to the parents and children.</p><p><b>Considerations in families with an apparent <a class="def" href="/books/n/gene/glossary/def-item/de-novo/"><i>de novo</i></a> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</b> When neither parent of a <a class="def" href="/books/n/gene/glossary/def-item/proband/">proband</a> with an <a class="def" href="/books/n/gene/glossary/def-item/autosomal-dominant/">autosomal dominant</a> condition has the pathogenic variant identified in the proband or clinical evidence of the disorder, the pathogenic variant is likely <i>de novo</i>. However, non-medical explanations including <a class="def" href="/books/n/gene/glossary/def-item/alternate-paternity/">alternate paternity</a> or maternity (e.g., with assisted reproduction) and undisclosed adoption could also be explored.</p><p><b>Family planning</b></p><ul><li class="half_rhythm"><div>The optimal time for determination of genetic risk, clarification of <a class="def" href="/books/n/gene/glossary/def-item/carrier/">carrier</a> status, and discussion of the availability of prenatal testing is before pregnancy.</div></li><li class="half_rhythm"><div>It is appropriate to offer <a class="def" href="/books/n/gene/glossary/def-item/genetic-counseling/">genetic counseling</a> (including discussion of potential risks to offspring and reproductive options) to young adults who are <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> or at risk.</div></li></ul><p><b>DNA banking</b> is the storage of DNA (typically extracted from white blood cells) for possible future use. Because it is likely that testing methodology and our understanding of genes, allelic variants, and diseases will improve in the future, consideration should be given to banking DNA of <a class="def" href="/books/n/gene/glossary/def-item/affected/">affected</a> individuals.</p></div><div id="nf2.Prenatal_Testing_and_Preimplantation"><h3>Prenatal Testing and Preimplantation Genetic Diagnosis</h3><p>Once the <i>NF2</i> <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a> has been identified in the family, prenatal testing for a pregnancy at increased risk and <a class="def" href="/books/n/gene/glossary/def-item/preimplantation-genetic-diagnosis/">preimplantation genetic diagnosis</a> are possible.</p><p>Differences in perspective may exist among medical professionals and within families regarding the use of prenatal testing, particularly if the testing is being considered for the purpose of pregnancy termination rather than early diagnosis. While most centers would consider decisions regarding prenatal testing to be the choice of the parents, discussion of these issues is appropriate.</p></div></div><div id="nf2.Resources"><h2 id="_nf2_Resources_">Resources</h2><p>
<i>GeneReviews staff has selected the following disease-specific and/or umbrella
support organizations and/or registries for the benefit of individuals with this disorder
and their families. GeneReviews is not responsible for the information provided by other
organizations. For information on selection criteria, click <a href="/books/n/gene/app4/">here</a>.</i></p><ul><li class="half_rhythm"><div><b>Children's Tumor Foundation</b></div><div>95 Pine Street</div><div>16th Floor</div><div>New York NY 10005</div><div><b>Phone:</b> 800-323-7938 (toll-free); 212-344-6633</div><div><b>Fax:</b> 212-747-0004</div><div><b>Email:</b> info@ctf.org</div><div><a href="http://www.ctf.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.ctf.org</a></div></li><li class="half_rhythm"><div><b>My46 Trait Profile</b></div><div><a href="https://www.my46.org/trait-document?trait=Neurofibromatosis%20type%202&#x00026;parent=Genetic%20Syndromes&#x00026;type=profile" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Neurofibromatosis type 2</a></div></li><li class="half_rhythm"><div><b>National Library of Medicine Genetics Home Reference</b></div><div><a href="http://ghr.nlm.nih.gov/condition=neurofibromatosis2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Neurofibromatosis 2</a></div></li><li class="half_rhythm"><div><b>NCBI Genes and Disease</b></div><div><a href="/books/NBK22169/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Neurofibromatosis 2</a></div></li><li class="half_rhythm"><div><b>Neurofibromatosis Network</b></div><div>213 South Wheaton Avenue</div><div>Wheaton IL 60187</div><div><b>Phone:</b> 800-942-6825</div><div><b>Fax:</b> 630-510-8508</div><div><b>Email:</b> admin@nfnetwork.org</div><div><a href="https://nfnetwork.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.nfnetwork.org</a></div></li><li class="half_rhythm"><div><b>NF2 Review</b></div><div>c/o the House of Ear Institute</div><div>2100 West Third Street</div><div>Second Floor</div><div>Los Angeles CA 90057</div><div><b>Phone:</b> 213-483-4431</div><div><b>Fax:</b> 213-413-0950</div><div><b>Email:</b> mrspetitohead@hotmail.com</div></li><li class="half_rhythm"><div><b>NF2 Sharing Network</b></div><div>10074 Cabachon Court</div><div>Ellicott City MD 21042</div><div><b>Phone:</b> 410-461-5213</div></li><li class="half_rhythm"><div><b>Acoustic Neuroma Association (ANA)</b></div><div>600 Peachtree Parkway</div><div>Suite 108</div><div>Cumming GA 30041-6899</div><div><b>Phone:</b> 877-200-8211 (toll free); 770-205-8211</div><div><b>Fax:</b> 877-202-0239 (toll free); 770-205-0239</div><div><b>Email:</b> info@anausa.org</div><div><a href="http://www.anausa.org" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">www.anausa.org</a></div></li><li class="half_rhythm"><div><b>Children's Tumor Foundation: Ending Neurofibromatosis Through Research</b></div><div>95 Pine Street</div><div>16th Floor</div><div>New York NY 10005</div><div><b>Phone:</b> 800-323-7938 (toll-free); 212-344-6633</div><div><b>Fax:</b> 212-747-0004</div><div><b>Email:</b> info@ctf.org</div><div><a href="http://www.ctf.org/Learn-About-NF/Schwannomatosis.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Schwannomatosis</a></div></li><li class="half_rhythm"><div><b>Medline Plus</b></div><div><a href="http://www.nlm.nih.gov/medlineplus/neurofibromatosis.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Neurofibromatosis</a></div></li></ul></div><div id="nf2.Molecular_Genetics"><h2 id="_nf2_Molecular_Genetics_">Molecular Genetics</h2><p><i>Information in the Molecular Genetics and OMIM tables may differ from that elsewhere in the GeneReview: tables may contain more recent information. &#x02014;</i>ED.</p><div id="nf2.molgen.TA" class="table"><h3><span class="label">Table A.</span></h3><div class="caption"><p>Neurofibromatosis 2: Genes and Databases</p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1201/table/nf2.molgen.TA/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__nf2.molgen.TA_lrgtbl__"><table class="no_bottom_margin"><tbody><tr><th id="hd_b_nf2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;">Gene</th><th id="hd_b_nf2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;">Chromosome Locus</th><th id="hd_b_nf2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;">Protein</th><th id="hd_b_nf2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;">Locus-Specific Databases</th><th id="hd_b_nf2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;">HGMD</th><th id="hd_b_nf2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;">ClinVar</th></tr><tr><td headers="hd_b_nf2.molgen.TA_1_1_1_1" rowspan="1" colspan="1" style="vertical-align:top;"><a href="/gene/4771" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=gene"><i>NF2</i></a></td><td headers="hd_b_nf2.molgen.TA_1_1_1_2" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/genome/gdv/?context=gene&#x00026;acc=4771" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">22q12<wbr style="display:inline-block"></wbr>​.2</a></td><td headers="hd_b_nf2.molgen.TA_1_1_1_3" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.uniprot.org/uniprot/P35240" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">Merlin</a></td><td headers="hd_b_nf2.molgen.TA_1_1_1_4" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://databases.lovd.nl/shared/genes/NF2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NF2 database</a></td><td headers="hd_b_nf2.molgen.TA_1_1_1_5" rowspan="1" colspan="1" style="vertical-align:top;"><a href="http://www.hgmd.cf.ac.uk/ac/gene.php?gene=NF2" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NF2</a></td><td headers="hd_b_nf2.molgen.TA_1_1_1_6" rowspan="1" colspan="1" style="vertical-align:top;"><a href="https://www.ncbi.nlm.nih.gov/clinvar/?term=NF2[gene]" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NF2</a></td></tr></tbody></table></div><div><div><dl class="temp-labeled-list small"><dt></dt><dd><div id="nf2.TFA.1"><p class="no_margin">Data are compiled from the following standard references: <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> from
<a href="http://www.genenames.org/index.html" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">HGNC</a>;
<a class="def" href="/books/n/gene/glossary/def-item/chromosome/">chromosome</a> <a class="def" href="/books/n/gene/glossary/def-item/locus/">locus</a> from
<a href="http://www.omim.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">OMIM</a>;
protein from <a href="http://www.uniprot.org/" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">UniProt</a>.
For a description of databases (Locus Specific, HGMD, ClinVar) to which links are provided, click
<a href="/books/n/gene/app1/">here</a>.</p></div></dd></dl></div></div></div><div id="nf2.molgen.TB" class="table"><h3><span class="label">Table B.</span></h3><div class="caption"><p>OMIM Entries for Neurofibromatosis 2 (<a href="/omim/101000,607379" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">View All in OMIM</a>) </p></div><p class="large-table-link" style="display:none"><span class="right"><a href="/books/NBK1201/table/nf2.molgen.TB/?report=objectonly" target="object">View in own window</a></span></p><div class="large_tbl" id="__nf2.molgen.TB_lrgtbl__"><table><tbody><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/101000" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">101000</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NEUROFIBROMATOSIS, TYPE II; NF2</td></tr><tr><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">
<a href="/omim/607379" ref="pagearea=body&amp;targetsite=entrez&amp;targetcat=term&amp;targettype=omim">607379</a></td><td rowspan="1" colspan="1" style="text-align:left;vertical-align:top;">NEUROFIBROMIN 2; NF2</td></tr></tbody></table></div></div><p><b>Gene structure.</b> The longest and predominant <i>NF2</i> transcript <a href="https://www.ncbi.nlm.nih.gov/nuccore/NM_000268.3" ref="pagearea=body&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">NM_000268.3</a> comprises 16 exons. <i>NF2</i> is widely expressed, producing <a class="def" href="/books/n/gene/glossary/def-item/mrna/">mRNA</a> transcripts in three different lengths of approximately 7, 4.4, and 2.6 kb. Two predominant and a number of minor transcript variants are produced by alternative <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> that encodes different protein <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a>. See <a href="/books/NBK1201/#nf2.molgen.TA">Table A</a>, <b>Gene</b> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, transcript, and protein information.</p><p><b>Pathogenic variants.</b> At least 400 <i>NF2</i> pathogenic variants have been described, with <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a>, <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>, and <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> variants and small deletions being the most common (<a href="/books/NBK1201/#nf2.molgen.TA">Table A</a>, <b>HGMD</b> and <b>Locus-Specific Databases</b>).</p><p>A wide variety of pathogenic variants have been identified in all <i>NF2</i> exons, except for the alternatively spliced exons.</p><ul><li class="half_rhythm"><div>90% of single-nucleotide variants are predicted to truncate the protein by introduction of a premature stop codon, a frameshift with premature termination, or a <a class="def" href="/books/n/gene/glossary/def-item/splicing/">splicing</a> alteration, supporting the view that loss of the protein's normal function is necessary for the development of tumors. C-to-T transitions in CGA codons causing pathogenic <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a> variants are an especially frequent occurrence.</div></li><li class="half_rhythm"><div>Fewer than 10% of detected pathogenic variants are <a class="def" href="/books/n/gene/glossary/def-item/in-frame/">in-frame</a> deletions and <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants, which may indicate that alteration of particular functional domains can abolish the <i>NF2</i> tumor suppressor activity [<a class="bk_pop" href="#nf2.REF.baser.2006.730">Baser et al 2006</a>].</div></li></ul><p><b>Normal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> The NF2 protein product has been named "merlin" (for <i>m</i>oezin-<i>e</i>zrin-<i>r</i>adixin-<i>l</i>ike prote<i>in</i>) because of the high homology to the 4.1 family of cytoskeletal-associated proteins. Alternatively, the name "schwannomin" has been proposed in recognition of its role in preventing schwannoma formation.</p><p>All 4.1 family members have a homologous <a class="def" href="/books/n/gene/glossary/def-item/domain/">domain</a> of approximately 270 amino acids at the N terminus. In the NF2 protein and its close relatives, this domain is followed by a long &#x003b1;-helical segment and a charged C-terminal domain. Protein 4.1, the best studied member of the family, plays a critical role in maintaining membrane stability and cell shape in the erythrocyte by connecting integral membrane proteins, glycophorin, and the anion channel to the spectrin-actin lattice of the cytoskeleton. Protein 4.1 is the only other family member in which pathogenic variants are known (hereditary elliptocytosis).</p><p>Two major alternative forms of the NF2 protein product exist, <a class="def" href="/books/n/gene/glossary/def-item/isoforms/">isoforms</a> 1 and 2. Additional alternative splices predicting other minor species have also been described. See <a href="/books/NBK1201/#nf2.molgen.TA">Table A</a>, <b>Gene</b> for a detailed summary of <a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a>, transcript, and protein isoforms.</p><p>Although the complete function of the NF2 protein remains elusive, studies suggest that "merlin" may coordinate the processes of growth-factor receptor signaling and cell adhesion. Varying use of this organizing activity by different types of cells could provide an explanation for the unique spectrum of tumors associated with NF2 deficiency in mammals [<a class="bk_pop" href="#nf2.REF.mcclatchey.2005.2265">McClatchey &#x00026; Giovannini 2005</a>]. More recently a critical role in the Hippo pathway mediated through suppression of Yap and Taz has been shown [<a class="bk_pop" href="#nf2.REF.reginensi.2016.12309">Reginensi et al 2016</a>].</p><p><b>Abnormal <a class="def" href="/books/n/gene/glossary/def-item/gene-product/">gene product</a>.</b> Abnormal NF2 protein is caused by either a somatic or a constitutional <a class="def" href="/books/n/gene/glossary/def-item/pathogenic-variant/">pathogenic variant</a>.</p><p>Attempts to identify truncated protein product have been unsuccessful in the main, although the non-truncated product from pathogenic <a class="def" href="/books/n/gene/glossary/def-item/missense/">missense</a> variants may have partial function. It is thought that <a class="def" href="/books/n/gene/glossary/def-item/nonsense-variant/">nonsense</a>-mediated decay may account for the lack of identifiable product from most variant types; however, this does not explain why phenotypes are more severe for this type of variant than for whole-<a class="def" href="/books/n/gene/glossary/def-item/gene/">gene</a> deletions.</p><p><b>Cancer and benign tumors.</b> Sporadic tumors (including schwannomas at any site, similarly for meningiomas) occurring as single tumors in the absence of any other findings of NF2 frequently harbor somatic variants in <i>NF2</i> that are <b>not</b> present in the <a class="def" href="/books/n/gene/glossary/def-item/germline/">germline</a>. In these circumstances predisposition to these tumors is not heritable [<a class="bk_pop" href="#nf2.REF.mohyuddin.2002.315">Mohyuddin et al 2002</a>, <a class="bk_pop" href="#nf2.REF.pathmanaban.2017.1123">Pathmanaban et al 2017</a>].</p></div><div id="nf2.References"><h2 id="_nf2_References_">References</h2><div id="nf2.Literature_Cited"><h3>Literature Cited</h3><ul class="simple-list"><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.aghi.2006.201">Aghi M, Kluwe L, Webster MT, Jacoby LB, Barker FG 2nd, Ojemann RG, Mautner VF, MacCollin M. Unilateral vestibular schwannoma with other neurofibromatosis type 2-related tumors: clinical and molecular study of a unique phenotype. <span><span class="ref-journal">J Neurosurg. </span>2006;<span class="ref-vol">104</span>:201–7.</span> [<a href="/pubmed/16509493" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16509493</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.balasubramaniam.2007.447">Balasubramaniam A, Shannon P, Hodaie M, Laperriere N, Michaels H, Guha A. Glioblastoma multiforme after stereotactic radiotherapy for acoustic neuroma: case report and review of the literature. <span><span class="ref-journal">Neuro Oncol. </span>2007;<span class="ref-vol">9</span>:447–53.</span> [<a href="/pmc/articles/PMC1994102/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1994102</span></a>] [<a href="/pubmed/17704364" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17704364</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.baser.2000.998">Baser ME, Evans DG, Jackler RK, Sujansky E, Rubinstein A. Malignant peripheral nerve sheath tumours, radiotherapy and neurofibromatosis 2. <span><span class="ref-journal">Br J Cancer. </span>2000;<span class="ref-vol">82</span>:998.</span> [<a href="/pmc/articles/PMC2374414/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2374414</span></a>] [<a href="/pubmed/10732777" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10732777</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.baser.2002.715">Baser ME, Friedman JM, Aeschliman D, Joe H, Wallace AJ, Ramsden RT, Evans DG. Predictors of the risk of mortality in neurofibromatosis 2. <span><span class="ref-journal">Am J Hum Genet. </span>2002;<span class="ref-vol">71</span>:715–23.</span> [<a href="/pmc/articles/PMC378530/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC378530</span></a>] [<a href="/pubmed/12235555" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12235555</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.baser.2006.730">Baser ME, Friedman JM, Evans DG. Increasing the specificity of diagnostic criteria for schwannomatosis. <span><span class="ref-journal">Neurology. </span>2006;<span class="ref-vol">66</span>:730–2.</span> [<a href="/pubmed/16534111" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16534111</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.baser.2004.231">Baser ME, Kuramoto L, Joe H, Friedman JM, Wallace AJ, Gillespie JE, Ramsden RT, Evans DG. Genotype-phenotype correlations for nervous system tumors in neurofibromatosis 2: a population-based study. <span><span class="ref-journal">Am J Hum Genet. </span>2004;<span class="ref-vol">75</span>:231–9.</span> [<a href="/pmc/articles/PMC1216057/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1216057</span></a>] [<a href="/pubmed/15190457" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15190457</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.baser.2005.540">Baser ME, Kuramoto L, Woods R, Joe H, Friedman JM, Wallace AJ, Ramsden RT, Olschwang S, Bijlsma E, Kalamarides M, Papi L, Kato R, Carroll J, Lazaro C, Joncourt F, Parry DM, Rouleau GA, Evans DG. The location of constitutional neurofibromatosis 2 (NF2) splice site mutations is associated with the severity of NF2. <span><span class="ref-journal">J Med Genet. </span>2005;<span class="ref-vol">42</span>:540–6.</span> [<a href="/pmc/articles/PMC1736092/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1736092</span></a>] [<a href="/pubmed/15994874" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15994874</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.christiaans.2011.93">Christiaans I, Kenter SB, Brink HC, van Os TA, Baas F, van den Munckhof P, Kidd AM, Hulsebos TJ. Germline SMARCB1 mutation and somatic NF2 mutations in familial multiple meningiomas. <span><span class="ref-journal">J Med Genet. </span>2011;<span class="ref-vol">48</span>:93–7.</span> [<a href="/pubmed/20930055" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20930055</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.chung.2018.47">Chung LK, Nguyen TP, Sheppard JP, Lagman C, Tenn S, Lee P, Kaprealian T, Chin R, Gopen Q, Yang I. A systematic review of radiosurgery versus surgery for neurofibromatosis type 2 vestibular schwannomas. <span><span class="ref-journal">World Neurosurg. </span>2018;<span class="ref-vol">109</span>:47–58.</span> [<a href="/pubmed/28882713" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28882713</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.cordeiro.2006.58">Cordeiro NJ, Gardner KR, Huson SM, Stewart H, Elston JS, Howard EL, Tullus KO, Pike MG. Renal vascular disease in neurofibromatosis type 2: association or coincidence? <span><span class="ref-journal">Dev Med Child Neurol. </span>2006;<span class="ref-vol">48</span>:58–9.</span> [<a href="/pubmed/16359595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16359595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.dow.2005.574">Dow G, Biggs N, Evans G, Gillespie J, Ramsden R, King A. Spinal tumors in neurofibromatosis type 2. Is emerging knowledge of genotype predictive of natural history? <span><span class="ref-journal">J Neurosurg Spine. </span>2005;<span class="ref-vol">2</span>:574–9.</span> [<a href="/pubmed/15945431" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15945431</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.evans.2005a.5">Evans DG, Baser ME, O'Reilly B, Rowe J, Gleeson M, Saeed S, King A, Huson SM, Kerr R, Thomas N, Irving R, MacFarlane R, Ferner R, McLeod R, Moffat D, Ramsden R. Management of the patient and family with neurofibromatosis 2: a consensus conference statement. <span><span class="ref-journal">Br J Neurosurg. </span>2005a;<span class="ref-vol">19</span>:5–12.</span> [<a href="/pubmed/16147576" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16147576</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.evans.1999.496">Evans DG, Birch JM, Ramsden RT. Paediatric presentation of type 2 neurofibromatosis. <span><span class="ref-journal">Arch Dis Child. </span>1999;<span class="ref-vol">81</span>:496–9.</span> [<a href="/pmc/articles/PMC1718148/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1718148</span></a>] [<a href="/pubmed/10569966" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 10569966</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.evans.2006.289">Evans DG, Birch JM, Ramsden RT, Sharif S, Baser ME. Malignant transformation and new primary tumours after therapeutic radiation for benign disease: substantial risks in certain tumour prone syndromes. <span><span class="ref-journal">J Med Genet. </span>2006;<span class="ref-vol">43</span>:289–94.</span> [<a href="/pmc/articles/PMC2563223/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2563223</span></a>] [<a href="/pubmed/16155191" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16155191</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.evans.2013.594">Evans DG, Bowers N, Huson SM, Wallace A. Mutation type and position varies between mosaic and inherited NF2 and correlates with disease severity. <span><span class="ref-journal">Clin Genet. </span>2013;<span class="ref-vol">83</span>:594–5.</span> [<a href="/pubmed/22989157" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 22989157</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.evans.2010.327">Evans DG, Howard E, Giblin C, Clancy T, Spencer H, Huson SM, Lalloo F. Birth incidence and prevalence of tumour prone syndromes: estimates from a UK genetic family register service. <span><span class="ref-journal">Am J Med Genet. </span>2010;<span class="ref-vol">152A</span>:327–32.</span> [<a href="/pubmed/20082463" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20082463</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.evans.1992.603">Evans DG, Huson SM, Donnai D, Neary W, Blair V, Newton V, Harris R. A clinical study of type 2 neurofibromatosis. <span><span class="ref-journal">Q J Med. </span>1992;<span class="ref-vol">84</span>:603–18.</span> [<a href="/pubmed/1484939" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 1484939</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.evans.2009.5032">Evans DG, Kalamarides M, Hunter-Schaedle K, Blakeley J, Allen J, Babovic-Vuskanovic D, Belzberg A, Bollag G, Chen R, DiTomaso E, Golfinos J, Harris G, Jacob A, Kalpana G, Karajannis M, Korf B, Kurzrock R, Law M, McClatchey A, Packer R, Roehm P, Rubenstein A, Slattery W 3rd, Tonsgard JH, Welling DB, Widemann B, Yohay K, Giovannini M. Consensus recommendations to accelerate clinical trials for neurofibromatosis type 2. <span><span class="ref-journal">Clin Cancer Res. </span>2009;<span class="ref-vol">15</span>:5032–9.</span> [<a href="/pmc/articles/PMC4513640/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4513640</span></a>] [<a href="/pubmed/19671848" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19671848</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.evans.2007a.354">Evans DG, Ramsden RT, Gokhale C, Bowers N, Huson SM, Wallace A. Should NF2 mutation screening be undertaken in patients with an apparently isolated vestibular schwannoma? <span><span class="ref-journal">Clin Genet. </span>2007a;<span class="ref-vol">71</span>:354–8.</span> [<a href="/pubmed/17470137" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17470137</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.evans.2007b.424">Evans DG, Ramsden RT, Shenton A, Gokhale C, Bowers NL, Huson SM, Pichert G, Wallace A. Mosaicism in neurofibromatosis type 2: an update of risk based on uni/bilaterality of vestibular schwannoma at presentation and sensitive mutation analysis including multiple ligation-dependent probe amplification. <span><span class="ref-journal">J Med Genet. </span>2007b;<span class="ref-vol">44</span>:424–8.</span> [<a href="/pmc/articles/PMC2598002/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC2598002</span></a>] [<a href="/pubmed/17307835" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 17307835</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.evans.2008.92">Evans DG, Ramsden RT, Shenton A, Gokhale C, Bowers N, Huson SM, Wallace AJ. What are the implications in individuals with unilateral vestibular schwannoma and other neurogenic tumors? <span><span class="ref-journal">J Neurosurg. </span>2008;<span class="ref-vol">108</span>:92–6.</span> [<a href="/pubmed/18173316" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18173316</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.evans.2000.897">Evans DG, Sainio M, Baser ME. Neurofibromatosis type 2. <span><span class="ref-journal">J Med Genet. </span>2000;<span class="ref-vol">37</span>:897–904.</span> [<a href="/pmc/articles/PMC1734496/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1734496</span></a>] [<a href="/pubmed/11106352" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11106352</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.evans.1998a.450">Evans DG, Trueman L, Wallace A, Collins S, Strachan T. Genotype/phenotype correlations in type 2 neurofibromatosis (NF2): evidence for more severe disease associated with truncating mutations. <span><span class="ref-journal">J Med Genet. </span>1998a;<span class="ref-vol">35</span>:450–5.</span> [<a href="/pmc/articles/PMC1051337/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1051337</span></a>] [<a href="/pubmed/9643284" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9643284</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.evans.1998b.727">Evans DG, Wallace AJ, Wu CL, Trueman L, Ramsden RT, Strachan T. Somatic mosaicism: a common cause of classic disease in tumor-prone syndromes? Lessons from type 2 neurofibromatosis. <span><span class="ref-journal">Am J Hum Genet. </span>1998b;<span class="ref-vol">63</span>:727–36.</span> [<a href="/pmc/articles/PMC1377392/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1377392</span></a>] [<a href="/pubmed/9718334" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9718334</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.evans.2005b.45">Evans DG, Watson C, King A, Wallace AJ, Baser ME. Multiple meningiomas: differential involvement of the NF2 gene in children and adults. <span><span class="ref-journal">J Med Genet. </span>2005b;<span class="ref-vol">42</span>:45–8.</span> [<a href="/pmc/articles/PMC1735900/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735900</span></a>] [<a href="/pubmed/15635074" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15635074</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.farschtschi.2016.475">Farschtschi S, Merker VL, Wolf D, Schuhmann M, Blakeley J, Plotkin SR, Hagel C, Mautner VF. Bevacizumab treatment for symptomatic spinal ependymomas in neurofibromatosis type 2. <span><span class="ref-journal">Acta Neurol Scand. </span>2016;<span class="ref-vol">133</span>:475–80.</span> [<a href="/pubmed/26369495" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26369495</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.feucht.2008.882">Feucht M, Griffiths B, Niem&#x000fc;ller I, Haase W, Richard G, Mautner VF. Neurofibromatosis 2 leads to higher incidence of strabismological and neuro-ophthalmological disorders. <span><span class="ref-journal">Acta Ophthalmol. </span>2008;<span class="ref-vol">86</span>:882–6.</span> [<a href="/pubmed/18976311" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 18976311</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.goutagny.2010.341">Goutagny S, Kalamarides M. Meningiomas and neurofibromatosis. <span><span class="ref-journal">J Neurooncol. </span>2010;<span class="ref-vol">99</span>:341–7.</span> [<a href="/pubmed/20714782" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20714782</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.hadfield.2010.567">Hadfield KD, Smith MJ, Trump D, Newman WG, Evans DG. SMARCB1 mutations are not a common cause of multiple meningiomas. <span><span class="ref-journal">J Med Genet. </span>2010;<span class="ref-vol">47</span>:567–8.</span> [<a href="/pubmed/20472658" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 20472658</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.hagel.2002.179">Hagel C, Lindenau M, Lamszus K, Kluwe L, Stavrou D, Mautner VF. Polyneuropathy in neurofibromatosis 2: clinical findings, molecular genetics and neuropathological alterations in sural nerve biopsy specimens. <span><span class="ref-journal">Acta Neuropathol (Berl). </span>2002;<span class="ref-vol">104</span>:179–87.</span> [<a href="/pubmed/12111361" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12111361</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.halliday.2017.657">Halliday D, Emmanouil B, Pretorius P, MacKeith S, Painter S, Tomkins H, Evans DG, Parry A. Genetic Severity Score predicts clinical phenotype in NF2. <span><span class="ref-journal">J Med Genet. </span>2017;<span class="ref-vol">54</span>:657–64.</span> [<a href="/pmc/articles/PMC5740551/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5740551</span></a>] [<a href="/pubmed/28848060" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28848060</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.halliday.2018.29">Halliday J, Rutherford SA, McCabe MG, Evans DG. An update on the diagnosis and treatment of vestibular schwannoma. <span><span class="ref-journal">Expert Rev Neurother. </span>2018;<span class="ref-vol">18</span>:29–39.</span> [<a href="/pubmed/29088993" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29088993</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.hexter.2015.699">Hexter A, Jones A, Joe H, Heap L, Smith MJ, Wallace AJ, Halliday D, Parry A, Taylor A, Raymond L, Shaw A, Afridi S, Obholzer R, Axon P, King AT. English Specialist NF2 Research Group, Friedman JM, Evans DG. Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. <span><span class="ref-journal">J Med Genet. </span>2015;<span class="ref-vol">52</span>:699–705.</span> [<a href="/pubmed/26275417" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26275417</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.kluwe.1998.228">Kluwe L, MacCollin M, Tatagiba M, Thomas S, Hazim W, Haase W, Mautner VF. Phenotypic variability associated with 14 splice-site mutations in the NF2 gene. <span><span class="ref-journal">Am J Med Genet. </span>1998;<span class="ref-vol">77</span>:228–33.</span> [<a href="/pubmed/9605590" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 9605590</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.kluwe.2003.109">Kluwe L, Mautner V, Heinrich B, Dezube R, Jacoby LB, Friedrich RE, MacCollin M. Molecular study of frequency of mosaicism in neurofibromatosis 2 patients with bilateral vestibular schwannomas. <span><span class="ref-journal">J Med Genet. </span>2003;<span class="ref-vol">40</span>:109–14.</span> [<a href="/pmc/articles/PMC1735360/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735360</span></a>] [<a href="/pubmed/12566519" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12566519</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.kros.2001.367">Kros J, de Greve K, van Tilborg A, Hop W, Pieterman H, Avezaat C, Lekanne Dit Deprez R, Zwarthoff E. NF2 status of meningiomas is associated with tumour localization and histology. <span><span class="ref-journal">J Pathol. </span>2001;<span class="ref-vol">194</span>:367–72.</span> [<a href="/pubmed/11439370" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11439370</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.masuda.2004.150">Masuda A, Fisher LM, Oppenheimer ML, Iqbal Z, Slattery WH. Hearing changes after diagnosis in neurofibromatosis type 2. <span><span class="ref-journal">Otol Neurotol. </span>2004;<span class="ref-vol">25</span>:150–4.</span> [<a href="/pubmed/15021775" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15021775</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.mcclatchey.2005.2265">McClatchey AI, Giovannini M. Membrane organization and tumorigenesis--the NF2 tumor suppressor, Merlin. <span><span class="ref-journal">Genes Dev. </span>2005;<span class="ref-vol">19</span>:2265–77.</span> [<a href="/pubmed/16204178" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16204178</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.morris.2017.474">Morris KA, Afridi SK, Evans DG, Hensiek AE, McCabe MG, Kellett M, Halliday D, Pretorius PM, Parry A. UK NF2 Research Group. The response of spinal cord ependymomas to bevacizumab in patients with neurofibromatosis Type 2. <span><span class="ref-journal">J Neurosurg Spine. </span>2017;<span class="ref-vol">26</span>:474–82.</span></div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.morris.2016.281">Morris KA, Golding JF, Axon PR, Afridi S, Blesing C, Ferner RE, Halliday D, Jena R, Pretorius PM, Evans DG, McCabe MG, Parry A, et al.  Bevacizumab in neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. <span><span class="ref-journal">Neurooncol Pract. </span>2016;<span class="ref-vol">3</span>:281–9.</span> [<a href="/pmc/articles/PMC5909937/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5909937</span></a>] [<a href="/pubmed/29692918" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 29692918</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.mohyuddin.2003.459">Mohyuddin A, Baser ME, Watson C, Purcell S, Ramsden RT, Heiberg A, Wallace AJ, Evans DG. Somatic mosaicism in neurofibromatosis 2: prevalence and risk of disease transmission to offspring. <span><span class="ref-journal">J Med Genet. </span>2003;<span class="ref-vol">40</span>:459–63.</span> [<a href="/pmc/articles/PMC1735486/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735486</span></a>] [<a href="/pubmed/12807969" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12807969</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.mohyuddin.2002.315">Mohyuddin A, Neary WJ, Wallace A, Wu CL, Purcell S, Reid H, Ramsden RT, Read A, Black G, Evans DG. Molecular genetic analysis of the NF2 gene in young patients with unilateral vestibular schwannomas. <span><span class="ref-journal">J Med Genet. </span>2002;<span class="ref-vol">39</span>:315–22.</span> [<a href="/pmc/articles/PMC1735110/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1735110</span></a>] [<a href="/pubmed/12011146" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12011146</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.nguyen.2005.247">Nguyen DQ, Chatterjee S, Bates R. Persistent hyperplastic primary vitreous in association with neurofibromatosis 2. <span><span class="ref-journal">J Pediatr Ophthalmol Strabismus. </span>2005;<span class="ref-vol">42</span>:247–9.</span> [<a href="/pubmed/16121558" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16121558</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.north.2016.172">North HJ, Mawman D, O'Driscoll M, Freeman SR, Rutherford SA, King AT, Hammerbeck-Ward C, Evans DG, Lloyd SK. Outcomes of cochlear implantation in patients with neurofibromatosis type 2. <span><span class="ref-journal">Cochlear Implants Int. </span>2016;<span class="ref-vol">17</span>:172–7.</span> [<a href="/pubmed/27691934" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27691934</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.pathmanaban.2017.1123">Pathmanaban ON, Sadler KV, Kamaly-Asl ID, King AT, Rutherford SA, Hammerbeck-Ward C, McCabe MG, Kilday JP, Beetz C, Poplawski NK, Evans DG, Smith MJ. Association of genetic predisposition with solitary schwannoma or meningioma in children and young adults. <span><span class="ref-journal">JAMA Neurol. </span>2017;<span class="ref-vol">74</span>:1123–9.</span> [<a href="/pmc/articles/PMC5710179/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5710179</span></a>] [<a href="/pubmed/28759666" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 28759666</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.patronas.2001.434">Patronas NJ, Courcoutsakis N, Bromley CM, Katzman GL, MacCollin M, Parry DM. Intramedullary and spinal canal tumors in patients with neurofibromatosis 2: MR imaging findings and correlation with genotype. <span><span class="ref-journal">Radiology. </span>2001;<span class="ref-vol">218</span>:434–42.</span> [<a href="/pubmed/11161159" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11161159</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.parry.1994.450">Parry DM, Eldridge R, Kaiser-Kupfer MI, Bouzas EA, Pikus A, Patronas N. Neurofibromatosis 2 (NF2): clinical characteristics of 63 affected individuals and clinical evidence for heterogeneity. <span><span class="ref-journal">Am J Med Genet. </span>1994;<span class="ref-vol">52</span>:450–61.</span> [<a href="/pubmed/7747758" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 7747758</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.parry.1996.529">Parry DM, MacCollin MM, Kaiser-Kupfer MI, Pulaski K, Nicholson HS, Bolesta M, Eldridge R, Gusella JF. Germ-line mutations in the neurofibromatosis 2 gene: correlations with disease severity and retinal abnormalities. <span><span class="ref-journal">Am J Hum Genet. </span>1996;<span class="ref-vol">59</span>:529–39.</span> [<a href="/pmc/articles/PMC1914910/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1914910</span></a>] [<a href="/pubmed/8751853" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 8751853</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.perry.2001.994">Perry A, Giannini C, Raghavan R, Scheithauer BW, Banerjee R, Margraf L, Bowers DC, Lytle RA, Newsham IF, Gutmann DH. Aggressive phenotypic and genotypic features in pediatric and NF2-associated meningiomas: a clinicopathologic study of 53 cases. <span><span class="ref-journal">J Neuropathol Exp Neurol. </span>2001;<span class="ref-vol">60</span>:994–1003.</span> [<a href="/pubmed/11589430" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11589430</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.plotkin.2009.358">Plotkin SR, Stemmer-Rachamimov AO, Barker FG 2nd, Halpin C, Padera TP, Tyrrell A, Sorensen AG, Jain RK, di Tomaso E. Hearing improvement after bevacizumab in patients with neurofibromatosis type 2. <span><span class="ref-journal">N Engl J Med. </span>2009;<span class="ref-vol">361</span>:358–67.</span> [<a href="/pmc/articles/PMC4816642/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4816642</span></a>] [<a href="/pubmed/19587327" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 19587327</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.reginensi.2016.12309">Reginensi A, Enderle L, Gregorieff A, Johnson RL, Wrana JL, McNeill H. A critical role for NF2 and the Hippo pathway in branching morphogenesis. <span><span class="ref-journal">Nat Commun. </span>2016;<span class="ref-vol">7</span>:12309.</span> [<a href="/pmc/articles/PMC4974664/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC4974664</span></a>] [<a href="/pubmed/27480037" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27480037</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.rowe.2003.1288">Rowe JG, Radatz MW, Walton L, Soanes T, Rodgers J, Kemeny AA. Clinical experience with gamma knife stereotactic radiosurgery in the management of vestibular schwannomas secondary to type 2 neurofibromatosis. <span><span class="ref-journal">J Neurol Neurosurg Psychiatry. </span>2003;<span class="ref-vol">74</span>:1288–93.</span> [<a href="/pmc/articles/PMC1738689/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC1738689</span></a>] [<a href="/pubmed/12933938" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 12933938</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.ruggieri.2005.21">Ruggieri M, Iannetti P, Polizzi A, La Mantia I, Spalice A, Giliberto O, Platania N, Gabriele AL, Albanese V, Pavone L. Earliest clinical manifestations and natural history of neurofibromatosis type 2 (NF2) in childhood: a study of 24 patients. <span><span class="ref-journal">Neuropediatrics. </span>2005;<span class="ref-vol">36</span>:21–34.</span> [<a href="/pubmed/15776319" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15776319</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.ruggieri.2016.345">Ruggieri M, Pratic&#x000f2; AD, Serra A, Maiolino L, Cocuzza S, Di Mauro P, Licciardello L, Milone P, Privitera G, Belfiore G, Di Pietro M, Di Raimondo F, Romano A, Chiarenza A, Muglia M, Polizzi A, Evans DG. Childhood neurofibromatosis type 2 (NF2) and related disorders: from bench to bedside and biologically targeted therapies. <span><span class="ref-journal">Acta Otorhinolaryngol Ital. </span>2016;<span class="ref-vol">36</span>:345–67.</span> [<a href="/pmc/articles/PMC5225790/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5225790</span></a>] [<a href="/pubmed/27958595" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27958595</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.sakai.2005.332">Sakai T, Vallejo MC, Shannon KT. A parturient with neurofibromatosis type 2: anesthetic and obstetric considerations for delivery. <span><span class="ref-journal">Int J Obstet Anesth. </span>2005;<span class="ref-vol">14</span>:332–5.</span> [<a href="/pubmed/16140520" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16140520</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.slattery.2004.811">Slattery WH 3rd, Fisher LM, Iqbal Z, Oppenhiemer M. Vestibular schwannoma growth rates in neurofibromatosis type 2 natural history consortium subjects. <span><span class="ref-journal">Otol Neurotol. </span>2004;<span class="ref-vol">25</span>:811–7.</span> [<a href="/pubmed/15354016" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15354016</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.slusarz.2014.1197">Slusarz KM, Merker VL, Muzikansky A, Francis SA, Plotkin SR. Long-term toxicity of bevacizumab therapy in neurofibromatosis 2 patients. <span><span class="ref-journal">Cancer Chemother Pharmacol. </span>2014;<span class="ref-vol">73</span>:1197–204.</span> [<a href="/pubmed/24710627" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 24710627</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.smith.2011.261">Smith MJ, Higgs JE, Bowers NL, Halliday D, Patterson J, Gillespie J, Huson SM, Freeman SR, Lloyd S, Rutherford SA, King AT, Wallace AJ, Ramsden RT, Evans DG. Cranial meningiomas in 411 NF2 patients with proven gene mutations: Clear positional effect of mutations, but absence of female severity effect on age at onset. <span><span class="ref-journal">J Med Genet. </span>2011;<span class="ref-vol">48</span>:261–5.</span> [<a href="/pubmed/21278391" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 21278391</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.smith.2017.87">Smith MJ, Bowers NL, Bulman M, Gokhale C, Wallace AJ, King AT, Lloyd SK, Rutherford SA, Hammerbeck-Ward CL, Freeman SR, Evans DG. Revisiting neurofibromatosis type 2 diagnostic criteria to exclude LZTR1-related schwannomatosis. <span><span class="ref-journal">Neurology. </span>2017;<span class="ref-vol">88</span>:87–92.</span> [<a href="/pmc/articles/PMC5200853/" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pmc">PMC free article<span class="bk_prnt">: PMC5200853</span></a>] [<a href="/pubmed/27856782" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 27856782</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.smith.2016.250">Smith MJ, Urquhart JE, Harkness EF, Miles EK, Bowers NL, Byers HJ, Bulman M, Gokhale C, Wallace AJ, Newman WG, Evans DG. The Contribution of Whole Gene Deletions and Large Rearrangements to the Mutation Spectrum in Inherited Tumor Predisposing Syndromes. <span><span class="ref-journal">Hum Mutat. </span>2016;<span class="ref-vol">37</span>:250–6.</span> [<a href="/pubmed/26615784" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 26615784</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.sperfeld.2002.996">Sperfeld AD, Hein C, Schroder JM, Ludolph AC, Hanemann CO. Occurrence and characterization of peripheral nerve involvement in neurofibromatosis type 2. <span><span class="ref-journal">Brain. </span>2002;<span class="ref-vol">125</span>:996–1004.</span> [<a href="/pubmed/11960890" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 11960890</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.spiegel.2005.336">Spiegel JE, Hapgood A, Hess PE. Epidural anesthesia in a parturient with neurofibromatosis type 2 undergoing cesarean section. <span><span class="ref-journal">Int J Obstet Anesth. </span>2005;<span class="ref-vol">14</span>:336–9.</span> [<a href="/pubmed/16154348" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 16154348</span></a>]</div></li><li class="half_rhythm"><div class="bk_ref" id="nf2.REF.wallace.2004.368">Wallace AJ, Watson CJ, Oward E, Evans DG, Elles RG. Mutation scanning of the NF2 gene: an improved service based on meta-PCR/sequencing, dosage analysis, and loss of heterozygosity analysis. <span><span class="ref-journal">Genet Test. </span>2004;<span class="ref-vol">8</span>:368–80.</span> [<a href="/pubmed/15684865" ref="pagearea=cite-ref&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">PubMed<span class="bk_prnt">: 15684865</span></a>]</div></li></ul></div></div><div id="nf2.Chapter_Notes"><h2 id="_nf2_Chapter_Notes_">Chapter Notes</h2><div id="nf2.Author_History"><h3>Author History</h3><p>D Gareth Evans, MD, FRCP (2004-present)<br />Mia MacCollin, MD; Harvard Medical School (1998-2004)</p></div><div id="nf2.Revision_History"><h3>Revision History</h3><ul><li class="half_rhythm"><div>15 March 2018 (ha) Comprehensive update posted live</div></li><li class="half_rhythm"><div>18 August 2011 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>19 May 2009 (me) Comprehensive update posted live</div></li><li class="half_rhythm"><div>6 June 2006 (me) Comprehensive update posted to live Web site</div></li><li class="half_rhythm"><div>6 April 2004 (me) Comprehensive update posted to live Web site</div></li><li class="half_rhythm"><div>29 October 2001 (me) Comprehensive update posted to live Web site</div></li><li class="half_rhythm"><div>14 October 1998 (pb) Review posted to live Web site</div></li><li class="half_rhythm"><div>5 August 1998 (mm) Original submission</div></li></ul></div></div><div id="bk_toc_contnr"></div></div></div>
            <div class="post-content"><div><div class="half_rhythm"><a href="/books/about/copyright/">Copyright</a> © 1993-2019, University of Washington, Seattle. GeneReviews is
a registered trademark of the University of Washington, Seattle. All rights
reserved.<p class="small">GeneReviews® chapters are owned by the University of Washington. Permission is
hereby granted to reproduce, distribute, and translate copies of content materials for
noncommercial research purposes only, provided that (i) credit for source (<a href="http://www.genereviews.org/" ref="pagearea=meta&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri">http://www.genereviews.org/</a>) and copyright (© 1993-2019 University of
Washington) are included with each copy; (ii) a link to the original material is provided
whenever the material is published elsewhere on the Web; and (iii) reproducers,
distributors, and/or translators comply with the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>. No further modifications are allowed. For clarity, excerpts
of GeneReviews chapters for use in lab reports and clinic notes are a permitted
use.</p><p class="small">For more information, see the <a href="/books/n/gene/GRcopyright_permiss/">GeneReviews® Copyright Notice and Usage
Disclaimer</a>.</p><p class="small">For questions regarding permissions or whether a specified use is allowed,
contact: <a href="mailto:dev@null" data-email="ude.wu@tssamda" class="oemail">ude.wu@tssamda</a>.</p></div><div class="small"><span class="label">Bookshelf ID: NBK1201</span><span class="label">PMID: <a href="/pubmed/20301380" title="PubMed record of this page" ref="pagearea=meta&amp;targetsite=entrez&amp;targetcat=link&amp;targettype=pubmed">20301380</a></span></div><div style="margin-top:2em" class="bk_noprnt"><a class="bk_cntns" href="/books/n/gene/">GeneReviews by Title</a><div class="pagination bk_noprnt"><a class="active page_link prev" href="/books/n/gene/nf1/" title="Previous page in this title">&lt; Prev</a><a class="active page_link next" href="/books/n/gene/ncl/" title="Next page in this title">Next &gt;</a></div></div></div></div>
            
        </div>

        <!-- Custom content below content -->
        <div class="col4">
            
        </div>
        
        
        <!-- Book content -->
        
        <!-- Custom contetnt below bottom nav -->
        <div class="col5">
            
        </div>
    </div>

    <div id="rightcolumn" class="four_col col last">
        <!-- Custom content above discovery portlets -->
        <div class="col6">
            <div id="ncbi_share_book"><a href="#" class="ncbi_share" data-ncbi_share_config="popup:false,shorten:true" ref="id=NBK1201&amp;db=books">Share</a></div>

        </div>
        <div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Views</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PDF_download" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/NBK1201/?report=reader">PubReader</a></li><li><a href="/books/NBK1201/?report=printable">Print View</a></li><li><a data-jig="ncbidialog" href="#_ncbi_dlg_citbx_NBK1201" data-jigconfig="width:400,modal:true">Cite this Page</a><div id="_ncbi_dlg_citbx_NBK1201" style="display:none" title="Cite this Page"><div class="bk_tt">Evans DG. Neurofibromatosis 2. 1998 Oct 14 [Updated 2018 Mar 15]. In: Adam MP, Ardinger HH, Pagon RA, et al., editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993-2019. <span class="bk_cite_avail"></span></div></div></li><li><a href="/books/NBK1201/pdf/Bookshelf_NBK1201.pdf">PDF version of this page</a> (746K)</li><li><a href="#" class="toggle-glossary-link" title="Enable/disable links to the glossary">Disable Glossary Links</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>In this GeneReview</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="page-toc" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="#nf2.Summary" ref="log$=inpage&amp;link_id=inpage">Summary</a></li><li><a href="#nf2.Diagnosis" ref="log$=inpage&amp;link_id=inpage">Diagnosis</a></li><li><a href="#nf2.Clinical_Characteristics" ref="log$=inpage&amp;link_id=inpage">Clinical Characteristics</a></li><li><a href="#nf2.Genetically_Related_Allelic_Disorder" ref="log$=inpage&amp;link_id=inpage">Genetically Related (Allelic) Disorders</a></li><li><a href="#nf2.Differential_Diagnosis" ref="log$=inpage&amp;link_id=inpage">Differential Diagnosis</a></li><li><a href="#nf2.Management" ref="log$=inpage&amp;link_id=inpage">Management</a></li><li><a href="#nf2.Genetic_Counseling" ref="log$=inpage&amp;link_id=inpage">Genetic Counseling</a></li><li><a href="#nf2.Resources" ref="log$=inpage&amp;link_id=inpage">Resources</a></li><li><a href="#nf2.Molecular_Genetics" ref="log$=inpage&amp;link_id=inpage">Molecular Genetics</a></li><li><a href="#nf2.References" ref="log$=inpage&amp;link_id=inpage">References</a></li><li><a href="#nf2.Chapter_Notes" ref="log$=inpage&amp;link_id=inpage">Chapter Notes</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>GeneReviews Links</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="source-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="/books/n/gene/advanced/"><i>GeneReviews</i> Advanced Search</a></li><li><a href="/books/n/gene/glossary/"><i>GeneReviews</i> Glossary</a></li><li><a href="/books/n/gene/resource_mats/">Resource Materials</a> <span class="bk_hlight1">NEW FEATURE</span></li><li><a href="/books/n/gene/updates/">New in <i>GeneReviews</i></a></li><li><a href="/books/n/gene/authors/">Author List</a></li><li><a href="/books/n/gene/prospective_authors/">For Current/Prospective Authors</a></li><li><a href="/books/n/gene/GRpersonnel/"><i>GeneReviews</i> Personnel</a></li><li><a href="/books/n/gene/howto_linkin/">Download/Link to <i>GeneReviews</i></a></li><li><a href="/books/n/gene/contact_us/">Contact Us</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Tests in GTR by Gene</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="document-links" id="Shutter"></a></div><div class="portlet_content"><ul xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="simple-list"><li><a href="https://www.ncbi.nlm.nih.gov/gtr/tests/?term=4771[geneid]" ref="pagearea=document-links&amp;targetsite=external&amp;targetcat=link&amp;targettype=uri&amp;link_id=tests_in_gtr_by_gene">NF2</a></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Related information</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="discovery_db_links" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=omim&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_omim&amp;IdsFromResult=1484480" ref="log$=recordlinks">OMIM</a><div class="brieflinkpop offscreen_noflow">Related OMIM records</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pmc&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pmc_refs&amp;IdsFromResult=1484480" ref="log$=recordlinks">PMC</a><div class="brieflinkpop offscreen_noflow">PubMed Central citations</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=pubmed&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_pubmed_refs&amp;IdsFromResult=1484480" ref="log$=recordlinks">PubMed</a><div class="brieflinkpop offscreen_noflow">Links to PubMed</div></li><li class="brieflinkpopper"><a class="brieflinkpopperctrl" href="/books/?Db=gene&amp;DbFrom=books&amp;Cmd=Link&amp;LinkName=books_gene&amp;IdsFromResult=1484480" ref="log$=recordlinks">Gene</a><div class="brieflinkpop offscreen_noflow">Locus Links</div></li></ul></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Similar articles in PubMed</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="PBooksDiscovery_RA" id="Shutter"></a></div><div class="portlet_content"><ul><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301625" ref="ordinalpos=1&amp;linkpos=1&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Retinoblastoma</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Retinoblastoma<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Lohmann DR, Gallie BL. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/25434947" ref="ordinalpos=1&amp;linkpos=2&amp;log$=relatedarticles&amp;logdbfrom=pubmed">Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.</a><span class="source">[J Neurosurg. 2014]</span><div class="brieflinkpop offscreen_noflow">Long-term follow-up studies of Gamma Knife surgery for patients with neurofibromatosis Type 2.<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Sun S, Liu A. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">J Neurosurg. 2014 Dec; 121 Suppl:143-9. </em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301488" ref="ordinalpos=1&amp;linkpos=3&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Li-Fraumeni Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Li-Fraumeni Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Schneider K, Zelley K, Nichols KE, Garber J. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301463" ref="ordinalpos=1&amp;linkpos=4&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Carney Complex</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> Carney Complex<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Stratakis CA, Raygada M. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li><li class="brieflinkpopper two_line"><a class="brieflinkpopperctrl" href="/pubmed/20301661" ref="ordinalpos=1&amp;linkpos=5&amp;log$=relatedreviews&amp;logdbfrom=pubmed"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">PTEN</i> Hamartoma Tumor Syndrome</a><span class="source">[GeneReviews<sup>®</sup>. 1993]</span><div class="brieflinkpop offscreen_noflow"><span xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="invert">Review</span> <i xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance">PTEN</i> Hamartoma Tumor Syndrome<div class="brieflinkpopdesc"><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="author">Eng C. </em><em xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" class="cit">GeneReviews®. 1993</em></div></div></li></ul><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed_reviews&amp;uid=20301380" ref="ordinalpos=1&amp;log$=relatedreviews_seeall&amp;logdbfrom=pubmed">See reviews...</a><a class="seemore" href="/sites/entrez?db=pubmed&amp;cmd=link&amp;linkname=pubmed_pubmed&amp;uid=20301380" ref="ordinalpos=1&amp;log$=relatedarticles_seeall&amp;logdbfrom=pubmed">See all...</a></div></div><div class="portlet"><div class="portlet_head"><div class="portlet_title"><h3><span>Recent Activity</span></h3></div><a name="Shutter" sid="1" href="#" class="portlet_shutter" title="Show/hide content" remembercollapsed="true" pgsec_name="recent_activity" id="Shutter"></a></div><div class="portlet_content"><div xmlns:np="http://ncbi.gov/portal/XSLT/namespace" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" id="HTDisplay" class=""><div class="action"><a href="javascript:historyDisplayState('ClearHT')">Clear</a><a href="javascript:historyDisplayState('HTOff')" class="HTOn">Turn Off</a><a href="javascript:historyDisplayState('HTOn')" class="HTOff">Turn On</a></div><ul id="activity"><li class="ra_rcd ralinkpopper two_line"><a class="htb ralinkpopperctrl" ref="log$=activity&amp;linkpos=1" href="/portal/utils/pageresolver.fcgi?recordid=5e040f7675f66d18aabc5733">Neurofibromatosis 2 - GeneReviews®</a><div class="ralinkpop offscreen_noflow">Neurofibromatosis 2 - GeneReviews®<div class="brieflinkpopdesc"></div></div><div class="tertiary"></div></li></ul><p class="HTOn">Your browsing activity is empty.</p><p class="HTOff">Activity recording is turned off.</p><p id="turnOn" class="HTOff"><a href="javascript:historyDisplayState('HTOn')">Turn recording back on</a></p><a class="seemore" href="/sites/myncbi/recentactivity">See more...</a></div></div></div>
        
        <!-- Custom content below discovery portlets -->
        <div class="col7">
            
        </div>
    </div>
</div>

<!-- Custom content after all -->
<div class="col8">
    
</div>
<div class="col9">
    
</div>

<script type="text/javascript" src="/corehtml/pmc/js/jquery.scrollTo-1.4.2.js"></script>
<script type="text/javascript">
    (function($){
        $('.skiplink').each(function(i, item){
            var href = $($(item).attr('href'));
            href.attr('tabindex', '-1').addClass('skiptarget'); // ensure the target can receive focus
            $(item).on('click', function(event){
                event.preventDefault();
                $.scrollTo(href, 0, {
                    onAfter: function(){
                        href.focus();
                    }
                });
            });
        });
    })(jQuery);
</script>
                        </div>
                        <div class="bottom">
                            
                            <div id="NCBIFooter_dynamic">
    <a id="help-desk-link" class="help_desk" href="" target="_blank">Support Center</a>
    <a id="help-desk-link" class="help_desk" href="https://support.ncbi.nlm.nih.gov/ics/support/KBList.asp?Time=2019-12-25T20:40:06-05:00&amp;Snapshot=%2Fprojects%2Fbooks%2FPBooks@5.22&amp;Host=portal101&amp;ncbi_phid=CE887A1AE03F26D1000000000A9503B0&amp;ncbi_session=CE887A1AE040F751_2709SID&amp;from=https%3A%2F%2Fwww.ncbi.nlm.nih.gov%2Fbooks%2FNBK1201%2F&amp;Db=pmc&amp;folderID=134&amp;Ncbi_App=bookshelf&amp;Page=literature&amp;style=classic&amp;deptID=28049" target="_blank">Support Center</a>
    
</div>

                            <div class="footer" id="footer">
    
    <div class="subfooter"> </div><script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/preloaderWidget.js"> </script>
    <div id="external-disclaimer" class="offscreen_noflow">
        External link. Please review our <a href="https://www.nlm.nih.gov/privacy.html">privacy policy</a>.
    </div>    
    <div id="ncbifooter" class="contact_info">      
        <div id="footer-contents-right">
            <div id="nlm_thumb_logo">
                <a href="https://www.nlm.nih.gov" title="NLM">NLM</a>
            </div>
            <div id="nih_thumb_logo">
                <a href="https://www.nih.gov" title="NIH">NIH</a>
            </div>
            <div id="hhs_thumb_logo">
                <a href="https://www.hhs.gov" title="DHHS">DHHS</a>
            </div>
            <div id="usagov_thumb_logo">
                <a href="https://www.usa.gov" title="USA.gov">USA.gov</a>
            </div>         
        </div>
        
        <div id="footer-contents-left">
            <p class="address vcard">
                <span class="url">
                    <a class="fn url newdomain" href="https://www.ncbi.nlm.nih.gov">National Center for
                        Biotechnology Information</a>,
                </span> <span class="org url newdomain"><a href="https://www.nlm.nih.gov/">U.S. National Library of Medicine</a></span>
                <span class="adr">
                    <span class="street-address">8600 Rockville Pike</span>, <span class="locality">Bethesda</span>
                    <span class="region">MD</span>, <span class="postal-code">20894</span>
                    <span class="country-name">USA</span>
                </span>
            </p>
            
            <a href="/home/about/policies.shtml">Policies and Guidelines</a> | <a href="/home/about/contact.shtml">Contact</a>
        </div>
    </div>
    <script type="text/javascript" src="/portal/portal3rc.fcgi/rlib/js/InstrumentOmnitureBaseJS/InstrumentNCBIConfigJS/InstrumentNCBIBaseJS/InstrumentPageStarterJS.js?v=1"> </script>    
    <script type="text/javascript" src="/portal/portal3rc.fcgi/static/js/hfjs2.js"> </script>
</div>
                        </div>
                    </div>
                    <!--/.page-->
                </div>
                <!--/.wrap-->
            </div><!-- /.twelve_col -->
        </div>
        <!-- /.grid -->

        <span class="PAFAppResources"></span>
        
        <!-- BESelector tab -->
        
        
        
        <noscript><img alt="statistics" src="/stat?jsdisabled=true&amp;ncbi_db=books&amp;ncbi_pdid=book-part&amp;ncbi_acc=NBK1201&amp;ncbi_domain=gene&amp;ncbi_report=record&amp;ncbi_type=fulltext&amp;ncbi_objectid=&amp;ncbi_pcid=/NBK1201/&amp;ncbi_pagename=Neurofibromatosis 2 - GeneReviews® - NCBI Bookshelf&amp;ncbi_bookparttype=chapter&amp;ncbi_app=bookshelf" /></noscript>
        
        
        <!-- usually for JS scripts at page bottom -->
        <!--<component id="PageFixtures" label="styles"></component>-->
    

<!-- CE887A1AE040F751_2709SID /projects/books/PBooks@5.22 portal101 v4.1.r585844 Mon, May 06 2019 02:53:16 -->

<script type="text/javascript" src="//static.pubmed.gov/portal/portal3rc.fcgi/4176521/js/3879255/4121861/3501987/4008961/3893018/3821238/4062932/4123007/4087685/4076480/3921943/3400083/3426610.js" snapshot="books"></script></body>
</html>